| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 393 | 2026 | 1833 | 18.060 |
Why?
|
| Polymorphism, Single Nucleotide | 457 | 2026 | 2833 | 17.930 |
Why?
|
| Atherosclerosis | 134 | 2026 | 948 | 11.350 |
Why?
|
| Hypertension | 193 | 2024 | 1356 | 10.920 |
Why?
|
| Genetic Variation | 183 | 2026 | 1559 | 8.860 |
Why?
|
| Coronary Disease | 96 | 2026 | 624 | 8.780 |
Why?
|
| Genetic Predisposition to Disease | 293 | 2026 | 3436 | 8.710 |
Why?
|
| Blood Pressure | 147 | 2024 | 1345 | 7.770 |
Why?
|
| Polymorphism, Genetic | 119 | 2022 | 776 | 6.660 |
Why?
|
| Genetic Loci | 91 | 2025 | 353 | 6.430 |
Why?
|
| Genome, Human | 105 | 2026 | 1321 | 6.050 |
Why?
|
| Metabolome | 23 | 2026 | 326 | 5.130 |
Why?
|
| Humans | 1245 | 2026 | 131163 | 4.980 |
Why?
|
| Gene Frequency | 160 | 2026 | 729 | 4.970 |
Why?
|
| Middle Aged | 588 | 2026 | 28601 | 4.950 |
Why?
|
| Cardiovascular Diseases | 90 | 2026 | 2121 | 4.830 |
Why?
|
| Coronary Artery Disease | 80 | 2026 | 887 | 4.830 |
Why?
|
| Antihypertensive Agents | 60 | 2024 | 414 | 4.830 |
Why?
|
| Genotype | 251 | 2025 | 2595 | 4.810 |
Why?
|
| Exome | 75 | 2025 | 1061 | 4.710 |
Why?
|
| Hydrochlorothiazide | 44 | 2024 | 67 | 4.650 |
Why?
|
| Male | 786 | 2026 | 64957 | 4.340 |
Why?
|
| Female | 779 | 2026 | 70963 | 4.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 71 | 2026 | 1459 | 4.030 |
Why?
|
| Risk Factors | 282 | 2026 | 11074 | 3.980 |
Why?
|
| Alleles | 143 | 2025 | 1673 | 3.940 |
Why?
|
| Whole Genome Sequencing | 42 | 2026 | 362 | 3.920 |
Why?
|
| Metabolomics | 32 | 2026 | 501 | 3.590 |
Why?
|
| Lipids | 51 | 2026 | 569 | 3.490 |
Why?
|
| Genomics | 54 | 2026 | 1621 | 3.460 |
Why?
|
| Cholesterol, LDL | 64 | 2025 | 604 | 3.340 |
Why?
|
| Quantitative Trait Loci | 60 | 2026 | 317 | 3.330 |
Why?
|
| Models, Genetic | 61 | 2026 | 749 | 3.300 |
Why?
|
| Apolipoproteins E | 49 | 2024 | 187 | 3.280 |
Why?
|
| Phenotype | 178 | 2025 | 4497 | 3.240 |
Why?
|
| Genetic Linkage | 59 | 2022 | 461 | 3.160 |
Why?
|
| Prospective Studies | 134 | 2026 | 6459 | 3.020 |
Why?
|
| Genetic Association Studies | 55 | 2024 | 819 | 2.970 |
Why?
|
| Cohort Studies | 176 | 2026 | 5063 | 2.960 |
Why?
|
| Cholesterol, HDL | 63 | 2025 | 383 | 2.940 |
Why?
|
| Stroke | 44 | 2022 | 1061 | 2.890 |
Why?
|
| Aged | 324 | 2026 | 21025 | 2.870 |
Why?
|
| Triglycerides | 69 | 2025 | 602 | 2.830 |
Why?
|
| Linkage Disequilibrium | 70 | 2026 | 316 | 2.750 |
Why?
|
| Chromosome Mapping | 61 | 2026 | 1046 | 2.690 |
Why?
|
| Biomarkers | 83 | 2026 | 3385 | 2.660 |
Why?
|
| Alzheimer Disease | 27 | 2026 | 878 | 2.580 |
Why?
|
| Body Mass Index | 76 | 2025 | 1717 | 2.530 |
Why?
|
| Obesity | 55 | 2026 | 2426 | 2.470 |
Why?
|
| Adult | 335 | 2026 | 31282 | 2.450 |
Why?
|
| Diabetes Mellitus | 34 | 2026 | 889 | 2.370 |
Why?
|
| Multifactorial Inheritance | 29 | 2026 | 176 | 2.330 |
Why?
|
| Blood Glucose | 40 | 2026 | 1117 | 2.320 |
Why?
|
| Child Development Disorders, Pervasive | 9 | 2014 | 82 | 2.250 |
Why?
|
| Aging | 35 | 2026 | 1242 | 2.210 |
Why?
|
| Environmental Pollutants | 5 | 2016 | 78 | 2.130 |
Why?
|
| Case-Control Studies | 89 | 2026 | 3359 | 2.090 |
Why?
|
| DNA Methylation | 27 | 2026 | 1077 | 2.090 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 16 | 2024 | 35 | 2.080 |
Why?
|
| Atrial Fibrillation | 20 | 2025 | 738 | 1.990 |
Why?
|
| Haplotypes | 66 | 2025 | 519 | 1.990 |
Why?
|
| Renal Insufficiency, Chronic | 22 | 2023 | 853 | 1.990 |
Why?
|
| Computational Biology | 24 | 2021 | 862 | 1.950 |
Why?
|
| Alcohol Drinking | 15 | 2026 | 341 | 1.950 |
Why?
|
| Antibodies, Viral | 7 | 2024 | 1176 | 1.920 |
Why?
|
| Sequence Analysis, DNA | 48 | 2024 | 1692 | 1.920 |
Why?
|
| High-Throughput Nucleotide Sequencing | 26 | 2024 | 889 | 1.910 |
Why?
|
| Lipoprotein(a) | 24 | 2024 | 142 | 1.910 |
Why?
|
| Heart Failure | 31 | 2026 | 2332 | 1.890 |
Why?
|
| Genetic Markers | 42 | 2021 | 587 | 1.860 |
Why?
|
| Pharmacogenetics | 34 | 2022 | 201 | 1.830 |
Why?
|
| United States | 151 | 2026 | 12072 | 1.820 |
Why?
|
| Carotid Arteries | 18 | 2011 | 124 | 1.810 |
Why?
|
| Lipid Metabolism | 20 | 2021 | 387 | 1.770 |
Why?
|
| Software | 19 | 2026 | 733 | 1.760 |
Why?
|
| Proteomics | 18 | 2026 | 615 | 1.760 |
Why?
|
| Quantitative Trait, Heritable | 26 | 2021 | 102 | 1.760 |
Why?
|
| Incidence | 66 | 2026 | 3360 | 1.750 |
Why?
|
| Algorithms | 25 | 2025 | 1680 | 1.720 |
Why?
|
| Health Information Exchange | 3 | 2024 | 10 | 1.710 |
Why?
|
| Cholesterol | 33 | 2022 | 539 | 1.700 |
Why?
|
| Atenolol | 24 | 2019 | 43 | 1.690 |
Why?
|
| DNA, Mitochondrial | 13 | 2025 | 233 | 1.670 |
Why?
|
| Carotid Artery Diseases | 17 | 2016 | 130 | 1.670 |
Why?
|
| Mutation | 66 | 2026 | 6099 | 1.660 |
Why?
|
| Membrane Proteins | 33 | 2026 | 1590 | 1.640 |
Why?
|
| Spike Glycoprotein, Coronavirus | 4 | 2024 | 215 | 1.620 |
Why?
|
| Fasting | 23 | 2026 | 303 | 1.620 |
Why?
|
| Genetics, Population | 31 | 2026 | 178 | 1.610 |
Why?
|
| Gene-Environment Interaction | 16 | 2025 | 127 | 1.590 |
Why?
|
| Chromosomes, Human, Pair 9 | 13 | 2019 | 109 | 1.570 |
Why?
|
| Proportional Hazards Models | 45 | 2021 | 1410 | 1.530 |
Why?
|
| von Willebrand Factor | 14 | 2026 | 191 | 1.470 |
Why?
|
| Precision Medicine | 19 | 2026 | 388 | 1.450 |
Why?
|
| DNA Copy Number Variations | 25 | 2024 | 1029 | 1.440 |
Why?
|
| Body Height | 21 | 2024 | 192 | 1.440 |
Why?
|
| Diet | 19 | 2024 | 1121 | 1.410 |
Why?
|
| Databases, Genetic | 27 | 2021 | 504 | 1.400 |
Why?
|
| Angiopoietins | 10 | 2017 | 18 | 1.400 |
Why?
|
| Jamaica | 13 | 2019 | 29 | 1.380 |
Why?
|
| Myocardial Infarction | 29 | 2021 | 999 | 1.380 |
Why?
|
| Lipoprotein Lipase | 19 | 2015 | 60 | 1.370 |
Why?
|
| Diuretics | 19 | 2019 | 159 | 1.370 |
Why?
|
| Kidney | 31 | 2023 | 1282 | 1.360 |
Why?
|
| Fibrinogen | 15 | 2026 | 170 | 1.350 |
Why?
|
| C-Reactive Protein | 19 | 2022 | 450 | 1.340 |
Why?
|
| Proteins | 23 | 2019 | 1006 | 1.300 |
Why?
|
| Arteriosclerosis | 18 | 2004 | 109 | 1.300 |
Why?
|
| Risk Assessment | 57 | 2026 | 3711 | 1.280 |
Why?
|
| Glomerular Filtration Rate | 28 | 2022 | 566 | 1.240 |
Why?
|
| Molecular Sequence Annotation | 9 | 2021 | 146 | 1.240 |
Why?
|
| TCF Transcription Factors | 6 | 2010 | 14 | 1.240 |
Why?
|
| Epigenesis, Genetic | 20 | 2026 | 757 | 1.240 |
Why?
|
| Factor VIII | 9 | 2026 | 50 | 1.230 |
Why?
|
| Brain Ischemia | 15 | 2019 | 266 | 1.230 |
Why?
|
| Glutathione Transferase | 6 | 2019 | 148 | 1.220 |
Why?
|
| Troponin T | 11 | 2021 | 259 | 1.220 |
Why?
|
| Residence Characteristics | 13 | 2021 | 295 | 1.210 |
Why?
|
| Apolipoproteins A | 19 | 2014 | 51 | 1.200 |
Why?
|
| Cognition | 12 | 2024 | 829 | 1.190 |
Why?
|
| Mendelian Randomization Analysis | 18 | 2026 | 100 | 1.180 |
Why?
|
| Leukocytes | 10 | 2023 | 205 | 1.180 |
Why?
|
| Young Adult | 71 | 2026 | 10103 | 1.160 |
Why?
|
| Models, Statistical | 19 | 2021 | 483 | 1.160 |
Why?
|
| Lipoproteins | 23 | 2018 | 183 | 1.150 |
Why?
|
| Arsenic | 3 | 2015 | 48 | 1.140 |
Why?
|
| Blood Proteins | 7 | 2026 | 143 | 1.140 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 13 | 2022 | 47 | 1.140 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 6 | 2019 | 56 | 1.130 |
Why?
|
| Pharmacogenomic Variants | 10 | 2019 | 38 | 1.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 18 | 2017 | 992 | 1.110 |
Why?
|
| Smoking | 21 | 2021 | 932 | 1.100 |
Why?
|
| Apolipoproteins B | 20 | 2023 | 142 | 1.090 |
Why?
|
| Heart Diseases | 10 | 2015 | 499 | 1.080 |
Why?
|
| Population Health | 6 | 2023 | 35 | 1.080 |
Why?
|
| Genome | 16 | 2022 | 451 | 1.070 |
Why?
|
| Glutathione S-Transferase pi | 3 | 2019 | 25 | 1.070 |
Why?
|
| Pedigree | 51 | 2020 | 1677 | 1.060 |
Why?
|
| Cross-Sectional Studies | 50 | 2026 | 3829 | 1.050 |
Why?
|
| Nitric Oxide Synthase Type III | 10 | 2013 | 186 | 1.050 |
Why?
|
| Aged, 80 and over | 72 | 2026 | 6797 | 1.040 |
Why?
|
| Vaccines | 2 | 2022 | 388 | 1.040 |
Why?
|
| Texas | 25 | 2026 | 3686 | 1.030 |
Why?
|
| Chromosomes, Human, Pair 2 | 17 | 2019 | 121 | 1.030 |
Why?
|
| Risk | 34 | 2021 | 726 | 1.020 |
Why?
|
| Life Style | 16 | 2026 | 456 | 1.000 |
Why?
|
| Inflammation | 13 | 2026 | 1489 | 0.990 |
Why?
|
| Adolescent | 121 | 2026 | 20987 | 0.980 |
Why?
|
| Insulin Resistance | 18 | 2026 | 690 | 0.970 |
Why?
|
| Gene Expression Regulation | 29 | 2024 | 2323 | 0.970 |
Why?
|
| Adrenergic beta-Antagonists | 12 | 2019 | 216 | 0.950 |
Why?
|
| Death, Sudden, Cardiac | 12 | 2026 | 268 | 0.950 |
Why?
|
| Aluminum | 2 | 2016 | 14 | 0.950 |
Why?
|
| Hypercholesterolemia | 9 | 2024 | 230 | 0.940 |
Why?
|
| Computer Simulation | 25 | 2026 | 674 | 0.940 |
Why?
|
| Plaque, Atherosclerotic | 9 | 2026 | 150 | 0.940 |
Why?
|
| Sex Factors | 36 | 2026 | 1356 | 0.930 |
Why?
|
| Natriuretic Peptide, Brain | 11 | 2026 | 325 | 0.930 |
Why?
|
| Albuminuria | 12 | 2023 | 107 | 0.930 |
Why?
|
| Linear Models | 32 | 2020 | 688 | 0.930 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 165 | 0.910 |
Why?
|
| Age Factors | 36 | 2021 | 2825 | 0.900 |
Why?
|
| Longitudinal Studies | 34 | 2026 | 1490 | 0.900 |
Why?
|
| Intercellular Adhesion Molecule-1 | 7 | 2023 | 125 | 0.900 |
Why?
|
| Heterozygote | 29 | 2024 | 737 | 0.890 |
Why?
|
| Mosaicism | 6 | 2026 | 248 | 0.890 |
Why?
|
| Receptors, Cell Surface | 11 | 2024 | 420 | 0.890 |
Why?
|
| Epistasis, Genetic | 9 | 2020 | 96 | 0.880 |
Why?
|
| Lead | 2 | 2015 | 25 | 0.870 |
Why?
|
| Fetal Blood | 2 | 2016 | 176 | 0.870 |
Why?
|
| Autism Spectrum Disorder | 4 | 2019 | 450 | 0.870 |
Why?
|
| Flow Cytometry | 7 | 2018 | 765 | 0.870 |
Why?
|
| Genetic Diseases, Inborn | 11 | 2019 | 468 | 0.860 |
Why?
|
| Apolipoproteins | 17 | 2013 | 69 | 0.850 |
Why?
|
| Renin-Angiotensin System | 11 | 2021 | 104 | 0.840 |
Why?
|
| Base Sequence | 41 | 2022 | 2730 | 0.830 |
Why?
|
| Amino Acids | 6 | 2023 | 566 | 0.830 |
Why?
|
| Abortion, Spontaneous | 1 | 2025 | 81 | 0.830 |
Why?
|
| Peptide Fragments | 13 | 2026 | 687 | 0.830 |
Why?
|
| Dietary Fats | 8 | 2016 | 278 | 0.830 |
Why?
|
| Uric Acid | 11 | 2019 | 110 | 0.830 |
Why?
|
| Calmodulin-Binding Proteins | 7 | 2006 | 65 | 0.830 |
Why?
|
| Genes | 14 | 2016 | 308 | 0.820 |
Why?
|
| CpG Islands | 15 | 2026 | 337 | 0.800 |
Why?
|
| Prevalence | 35 | 2026 | 2701 | 0.800 |
Why?
|
| Child | 78 | 2025 | 26341 | 0.790 |
Why?
|
| Genetic Pleiotropy | 5 | 2019 | 25 | 0.780 |
Why?
|
| Meta-Analysis as Topic | 25 | 2019 | 169 | 0.780 |
Why?
|
| Child, Preschool | 52 | 2025 | 15110 | 0.780 |
Why?
|
| Databases, Nucleic Acid | 3 | 2013 | 70 | 0.770 |
Why?
|
| Lod Score | 25 | 2018 | 126 | 0.760 |
Why?
|
| Information Dissemination | 4 | 2019 | 194 | 0.760 |
Why?
|
| Follow-Up Studies | 45 | 2021 | 5196 | 0.760 |
Why?
|
| Gastrointestinal Microbiome | 7 | 2026 | 842 | 0.760 |
Why?
|
| Long QT Syndrome | 6 | 2022 | 86 | 0.760 |
Why?
|
| Menarche | 7 | 2024 | 31 | 0.760 |
Why?
|
| Insulin | 18 | 2022 | 1149 | 0.750 |
Why?
|
| Blood Platelets | 7 | 2022 | 313 | 0.740 |
Why?
|
| Seafood | 2 | 2012 | 10 | 0.730 |
Why?
|
| Nerve Tissue Proteins | 14 | 2022 | 1075 | 0.730 |
Why?
|
| Sleep Wake Disorders | 3 | 2025 | 204 | 0.730 |
Why?
|
| Electrocardiography | 16 | 2022 | 970 | 0.720 |
Why?
|
| Receptors, Adrenergic, beta-2 | 11 | 2019 | 57 | 0.720 |
Why?
|
| Carrier Proteins | 9 | 2024 | 993 | 0.720 |
Why?
|
| Public Health | 9 | 2025 | 269 | 0.710 |
Why?
|
| Calcinosis | 14 | 2013 | 180 | 0.710 |
Why?
|
| Environmental Exposure | 3 | 2015 | 298 | 0.700 |
Why?
|
| Lipase | 10 | 2014 | 91 | 0.700 |
Why?
|
| Regression Analysis | 24 | 2025 | 761 | 0.690 |
Why?
|
| Erythrocytes | 12 | 2021 | 186 | 0.690 |
Why?
|
| Promoter Regions, Genetic | 11 | 2023 | 1207 | 0.680 |
Why?
|
| Chlorthalidone | 12 | 2019 | 25 | 0.680 |
Why?
|
| Proteome | 6 | 2026 | 285 | 0.680 |
Why?
|
| Membrane Glycoproteins | 5 | 2020 | 405 | 0.680 |
Why?
|
| Medical Informatics | 3 | 2019 | 107 | 0.680 |
Why?
|
| Hyperglycemia | 10 | 2019 | 234 | 0.670 |
Why?
|
| Fatty Acids | 3 | 2016 | 377 | 0.670 |
Why?
|
| Gene Expression Profiling | 19 | 2026 | 1801 | 0.670 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2010 | 161 | 0.670 |
Why?
|
| Manganese | 3 | 2019 | 58 | 0.670 |
Why?
|
| Referral and Consultation | 2 | 2024 | 564 | 0.670 |
Why?
|
| Venous Thromboembolism | 7 | 2026 | 195 | 0.660 |
Why?
|
| Time Factors | 28 | 2026 | 6196 | 0.660 |
Why?
|
| Odds Ratio | 24 | 2023 | 1211 | 0.660 |
Why?
|
| Exons | 13 | 2023 | 759 | 0.660 |
Why?
|
| Reproducibility of Results | 34 | 2021 | 2904 | 0.650 |
Why?
|
| National Institutes of Health (U.S.) | 6 | 2019 | 136 | 0.650 |
Why?
|
| Metagenomics | 3 | 2026 | 116 | 0.650 |
Why?
|
| Cholesterol Ester Transfer Proteins | 8 | 2016 | 39 | 0.650 |
Why?
|
| P-Selectin | 5 | 2011 | 69 | 0.650 |
Why?
|
| Serine Endopeptidases | 8 | 2021 | 197 | 0.650 |
Why?
|
| Telomere Homeostasis | 2 | 2024 | 48 | 0.650 |
Why?
|
| Sleep Apnea Syndromes | 4 | 2026 | 96 | 0.640 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 11 | 2020 | 588 | 0.630 |
Why?
|
| Kidney Failure, Chronic | 12 | 2020 | 934 | 0.630 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2026 | 744 | 0.620 |
Why?
|
| Sleep | 5 | 2025 | 381 | 0.620 |
Why?
|
| Inheritance Patterns | 9 | 2019 | 127 | 0.610 |
Why?
|
| Sample Size | 10 | 2022 | 84 | 0.610 |
Why?
|
| Adiposity | 8 | 2025 | 209 | 0.610 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2025 | 514 | 0.610 |
Why?
|
| Mutation, Missense | 20 | 2023 | 919 | 0.610 |
Why?
|
| Chromosomes, Human, Pair 5 | 11 | 2016 | 108 | 0.610 |
Why?
|
| Carotid Intima-Media Thickness | 8 | 2018 | 77 | 0.600 |
Why?
|
| Adaptor Proteins, Signal Transducing | 9 | 2024 | 619 | 0.600 |
Why?
|
| Glycocholic Acid | 1 | 2019 | 1 | 0.590 |
Why?
|
| Proprotein Convertase 9 | 12 | 2026 | 108 | 0.590 |
Why?
|
| Uridine | 1 | 2019 | 31 | 0.590 |
Why?
|
| Phospholipases A2 | 3 | 2015 | 31 | 0.590 |
Why?
|
| Pyrrolidinones | 1 | 2019 | 22 | 0.580 |
Why?
|
| Principal Component Analysis | 8 | 2016 | 151 | 0.580 |
Why?
|
| Mortality | 3 | 2020 | 264 | 0.580 |
Why?
|
| Renin | 9 | 2022 | 75 | 0.580 |
Why?
|
| Neoplasm Proteins | 6 | 2019 | 680 | 0.570 |
Why?
|
| Genetics, Medical | 8 | 2019 | 119 | 0.570 |
Why?
|
| Serum | 2 | 2020 | 41 | 0.570 |
Why?
|
| Potassium | 5 | 2017 | 263 | 0.570 |
Why?
|
| Vaccination | 2 | 2023 | 1060 | 0.570 |
Why?
|
| Dementia | 5 | 2026 | 436 | 0.560 |
Why?
|
| Peptidyl-Dipeptidase A | 8 | 2007 | 57 | 0.560 |
Why?
|
| Seroepidemiologic Studies | 4 | 2024 | 158 | 0.560 |
Why?
|
| Tunica Intima | 10 | 2010 | 61 | 0.560 |
Why?
|
| DNA | 23 | 2023 | 1399 | 0.560 |
Why?
|
| Biometry | 1 | 2019 | 101 | 0.560 |
Why?
|
| Apolipoprotein C-III | 10 | 2015 | 46 | 0.560 |
Why?
|
| Heart | 7 | 2020 | 650 | 0.550 |
Why?
|
| DNA-Binding Proteins | 18 | 2023 | 1939 | 0.550 |
Why?
|
| Epidemiologic Studies | 2 | 2015 | 40 | 0.550 |
Why?
|
| Bayes Theorem | 7 | 2023 | 311 | 0.540 |
Why?
|
| Kininogens | 3 | 2024 | 3 | 0.540 |
Why?
|
| Sodium | 9 | 2022 | 280 | 0.540 |
Why?
|
| Inflammation Mediators | 4 | 2026 | 226 | 0.540 |
Why?
|
| Homozygote | 17 | 2019 | 533 | 0.540 |
Why?
|
| White Matter | 6 | 2023 | 219 | 0.540 |
Why?
|
| Europe | 19 | 2022 | 365 | 0.530 |
Why?
|
| Hospitalization | 10 | 2024 | 1950 | 0.530 |
Why?
|
| Feeding Behavior | 4 | 2022 | 715 | 0.530 |
Why?
|
| Carnitine | 2 | 2026 | 70 | 0.520 |
Why?
|
| Pesticides | 2 | 2018 | 26 | 0.520 |
Why?
|
| Transcription Factors | 17 | 2020 | 2406 | 0.520 |
Why?
|
| Coronary Vessels | 12 | 2026 | 521 | 0.520 |
Why?
|
| Body Size | 7 | 2019 | 62 | 0.520 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 8 | 2014 | 25 | 0.520 |
Why?
|
| Gout | 6 | 2022 | 169 | 0.520 |
Why?
|
| Antigens, CD | 4 | 2026 | 410 | 0.520 |
Why?
|
| Up-Regulation | 7 | 2020 | 825 | 0.510 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2026 | 650 | 0.510 |
Why?
|
| Apolipoprotein L1 | 4 | 2022 | 13 | 0.510 |
Why?
|
| Hyperlipoproteinemia Type II | 5 | 2024 | 119 | 0.510 |
Why?
|
| Anodontia | 4 | 2018 | 33 | 0.510 |
Why?
|
| Lipoproteins, LDL | 10 | 2013 | 119 | 0.510 |
Why?
|
| Cognition Disorders | 5 | 2016 | 556 | 0.500 |
Why?
|
| DNA Mutational Analysis | 11 | 2021 | 775 | 0.500 |
Why?
|
| Dyslipidemias | 8 | 2025 | 256 | 0.500 |
Why?
|
| Epoxide Hydrolases | 5 | 2016 | 35 | 0.500 |
Why?
|
| Mitochondrial Proteins | 9 | 2020 | 283 | 0.500 |
Why?
|
| Apolipoproteins C | 8 | 2006 | 11 | 0.500 |
Why?
|
| Systole | 13 | 2018 | 195 | 0.500 |
Why?
|
| Logistic Models | 16 | 2024 | 1797 | 0.500 |
Why?
|
| DNA, Intergenic | 2 | 2015 | 18 | 0.490 |
Why?
|
| Predictive Value of Tests | 18 | 2026 | 2304 | 0.490 |
Why?
|
| Cell Adhesion Molecules | 5 | 2024 | 223 | 0.490 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2016 | 14 | 0.490 |
Why?
|
| Receptors, Adrenergic, beta | 5 | 2007 | 42 | 0.490 |
Why?
|
| Molecular Sequence Data | 35 | 2016 | 3464 | 0.490 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 9 | 2017 | 91 | 0.490 |
Why?
|
| Aldosterone | 6 | 2022 | 56 | 0.490 |
Why?
|
| Glucose Intolerance | 3 | 2021 | 80 | 0.490 |
Why?
|
| Epithelial Sodium Channels | 5 | 2022 | 15 | 0.480 |
Why?
|
| Kidney Diseases | 9 | 2022 | 477 | 0.480 |
Why?
|
| Population Surveillance | 7 | 2021 | 396 | 0.480 |
Why?
|
| Animals | 73 | 2024 | 33912 | 0.480 |
Why?
|
| Angiotensinogen | 10 | 2007 | 24 | 0.470 |
Why?
|
| Telomerase | 2 | 2024 | 154 | 0.470 |
Why?
|
| Environmental Monitoring | 1 | 2016 | 99 | 0.470 |
Why?
|
| Mercury | 2 | 2015 | 31 | 0.470 |
Why?
|
| Arrhythmias, Cardiac | 6 | 2026 | 482 | 0.470 |
Why?
|
| Receptors, LDL | 7 | 2016 | 106 | 0.460 |
Why?
|
| Mitochondria | 4 | 2025 | 785 | 0.460 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2017 | 49 | 0.460 |
Why?
|
| Mexican Americans | 14 | 2014 | 162 | 0.460 |
Why?
|
| Chromosomes, Human, Y | 2 | 2026 | 52 | 0.460 |
Why?
|
| Genotyping Techniques | 7 | 2021 | 110 | 0.450 |
Why?
|
| Chromosomes, Human | 13 | 2015 | 118 | 0.450 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2023 | 597 | 0.450 |
Why?
|
| Repressor Proteins | 9 | 2023 | 760 | 0.450 |
Why?
|
| Nitric Oxide Synthase | 7 | 2005 | 170 | 0.450 |
Why?
|
| Germ-Line Mutation | 6 | 2025 | 373 | 0.450 |
Why?
|
| Muscle Hypotonia | 5 | 2016 | 194 | 0.450 |
Why?
|
| Prediabetic State | 3 | 2018 | 68 | 0.450 |
Why?
|
| Epidemiologic Research Design | 1 | 2015 | 7 | 0.450 |
Why?
|
| Diabetic Nephropathies | 3 | 2023 | 115 | 0.440 |
Why?
|
| Vegetables | 2 | 2019 | 267 | 0.440 |
Why?
|
| Research Design | 13 | 2019 | 716 | 0.440 |
Why?
|
| Amyloid beta-Protein Precursor | 4 | 2025 | 112 | 0.440 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2024 | 484 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 12 | 10 | 2014 | 91 | 0.440 |
Why?
|
| Lead Poisoning | 1 | 2015 | 5 | 0.440 |
Why?
|
| Microcephaly | 5 | 2020 | 347 | 0.440 |
Why?
|
| Health Planning Guidelines | 1 | 2015 | 33 | 0.440 |
Why?
|
| Socioeconomic Factors | 8 | 2019 | 915 | 0.440 |
Why?
|
| Genome, Viral | 5 | 2026 | 165 | 0.440 |
Why?
|
| MicroRNAs | 5 | 2024 | 889 | 0.440 |
Why?
|
| Metals, Heavy | 1 | 2015 | 26 | 0.430 |
Why?
|
| Sex Characteristics | 12 | 2021 | 323 | 0.430 |
Why?
|
| Disease Susceptibility | 9 | 2023 | 274 | 0.430 |
Why?
|
| Hemeproteins | 1 | 2014 | 8 | 0.430 |
Why?
|
| Developing Countries | 1 | 2017 | 305 | 0.430 |
Why?
|
| Introns | 11 | 2017 | 278 | 0.430 |
Why?
|
| Diastole | 11 | 2019 | 181 | 0.430 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 2 | 2015 | 29 | 0.430 |
Why?
|
| Leukocyte Count | 6 | 2020 | 246 | 0.430 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 6 | 2019 | 32 | 0.420 |
Why?
|
| Cerebral Small Vessel Diseases | 3 | 2020 | 10 | 0.420 |
Why?
|
| Research | 2 | 2021 | 264 | 0.420 |
Why?
|
| Calcium-Binding Proteins | 7 | 2023 | 325 | 0.420 |
Why?
|
| Cytoskeletal Proteins | 5 | 2020 | 258 | 0.420 |
Why?
|
| Point Mutation | 7 | 2025 | 333 | 0.420 |
Why?
|
| Aryldialkylphosphatase | 4 | 2011 | 9 | 0.420 |
Why?
|
| Blood Cells | 2 | 2025 | 53 | 0.420 |
Why?
|
| Epigenomics | 5 | 2021 | 181 | 0.420 |
Why?
|
| Tetrazoles | 5 | 2019 | 70 | 0.420 |
Why?
|
| Heart Rate | 7 | 2019 | 577 | 0.420 |
Why?
|
| Transcriptome | 8 | 2026 | 1103 | 0.420 |
Why?
|
| Heme | 1 | 2014 | 46 | 0.420 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 82 | 0.410 |
Why?
|
| Neoplasms | 7 | 2025 | 3016 | 0.410 |
Why?
|
| Hematopoiesis | 5 | 2024 | 213 | 0.400 |
Why?
|
| Cardiology | 4 | 2022 | 514 | 0.400 |
Why?
|
| Siblings | 13 | 2009 | 201 | 0.400 |
Why?
|
| Evolution, Molecular | 8 | 2026 | 644 | 0.400 |
Why?
|
| Gene Regulatory Networks | 8 | 2017 | 373 | 0.400 |
Why?
|
| Family Health | 15 | 2015 | 240 | 0.400 |
Why?
|
| Prognosis | 23 | 2026 | 4886 | 0.400 |
Why?
|
| Benzimidazoles | 5 | 2019 | 161 | 0.400 |
Why?
|
| Creatinine | 12 | 2023 | 398 | 0.400 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 3 | 2019 | 12 | 0.400 |
Why?
|
| Metabolic Networks and Pathways | 6 | 2018 | 192 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 16 | 8 | 2021 | 147 | 0.400 |
Why?
|
| Presenilin-2 | 2 | 2025 | 18 | 0.400 |
Why?
|
| Data Collection | 2 | 2015 | 370 | 0.390 |
Why?
|
| Genetic Testing | 16 | 2022 | 1106 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 188 | 0.390 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 6 | 2025 | 150 | 0.390 |
Why?
|
| Internet | 2 | 2014 | 420 | 0.390 |
Why?
|
| Surveys and Questionnaires | 10 | 2022 | 4066 | 0.390 |
Why?
|
| Poverty | 1 | 2017 | 462 | 0.390 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2020 | 170 | 0.390 |
Why?
|
| Birth Weight | 1 | 2015 | 347 | 0.390 |
Why?
|
| Receptors, Immunologic | 3 | 2026 | 126 | 0.390 |
Why?
|
| Factor VII | 4 | 2022 | 17 | 0.390 |
Why?
|
| Lipoproteins, HDL | 8 | 2021 | 97 | 0.380 |
Why?
|
| Nervous System Diseases | 4 | 2019 | 395 | 0.380 |
Why?
|
| Monocytes | 5 | 2018 | 335 | 0.380 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 6 | 2017 | 19 | 0.380 |
Why?
|
| RNA Splicing | 3 | 2023 | 235 | 0.380 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2023 | 58 | 0.370 |
Why?
|
| Vascular Diseases | 4 | 2026 | 146 | 0.370 |
Why?
|
| ROC Curve | 12 | 2021 | 613 | 0.370 |
Why?
|
| Diabetic Angiopathies | 2 | 2015 | 66 | 0.370 |
Why?
|
| Tryptophan | 4 | 2021 | 84 | 0.370 |
Why?
|
| Paternal Age | 1 | 2012 | 15 | 0.370 |
Why?
|
| Consanguinity | 5 | 2020 | 115 | 0.370 |
Why?
|
| Waist-Hip Ratio | 10 | 2021 | 53 | 0.370 |
Why?
|
| Drinking Water | 1 | 2012 | 15 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2023 | 3763 | 0.370 |
Why?
|
| Glucose | 9 | 2023 | 853 | 0.370 |
Why?
|
| Genetic Heterogeneity | 10 | 2019 | 132 | 0.370 |
Why?
|
| Neuropsychological Tests | 7 | 2024 | 960 | 0.370 |
Why?
|
| Metabolic Syndrome | 6 | 2025 | 369 | 0.370 |
Why?
|
| Acetyltransferases | 3 | 2020 | 75 | 0.360 |
Why?
|
| Quality Control | 9 | 2021 | 116 | 0.360 |
Why?
|
| Population Groups | 7 | 2025 | 30 | 0.360 |
Why?
|
| Connectin | 4 | 2026 | 30 | 0.360 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 265 | 0.360 |
Why?
|
| Heart Conduction System | 4 | 2018 | 164 | 0.360 |
Why?
|
| Heart Defects, Congenital | 5 | 2025 | 1889 | 0.360 |
Why?
|
| Multivariate Analysis | 12 | 2019 | 1378 | 0.360 |
Why?
|
| Maternal Age | 1 | 2012 | 136 | 0.360 |
Why?
|
| Schizophrenia | 3 | 2025 | 324 | 0.360 |
Why?
|
| Chronic Disease | 9 | 2026 | 1246 | 0.360 |
Why?
|
| Carotid Artery, Common | 5 | 2011 | 59 | 0.350 |
Why?
|
| Blood Coagulation | 2 | 2026 | 134 | 0.350 |
Why?
|
| Colonic Neoplasms | 2 | 2008 | 262 | 0.350 |
Why?
|
| Open Reading Frames | 5 | 2021 | 198 | 0.350 |
Why?
|
| Apolipoprotein A-I | 10 | 2011 | 80 | 0.350 |
Why?
|
| Autistic Disorder | 2 | 2012 | 398 | 0.350 |
Why?
|
| Immunity | 3 | 2019 | 178 | 0.350 |
Why?
|
| Antibody Formation | 2 | 2023 | 227 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 8 | 5 | 2019 | 77 | 0.350 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2022 | 86 | 0.340 |
Why?
|
| Peripheral Arterial Disease | 3 | 2026 | 326 | 0.340 |
Why?
|
| Systems Biology | 1 | 2011 | 60 | 0.340 |
Why?
|
| Microfilament Proteins | 7 | 2018 | 269 | 0.340 |
Why?
|
| Heterotaxy Syndrome | 2 | 2024 | 61 | 0.340 |
Why?
|
| Phylogeny | 9 | 2026 | 689 | 0.330 |
Why?
|
| Arteries | 6 | 2024 | 208 | 0.330 |
Why?
|
| Codon, Nonsense | 6 | 2018 | 136 | 0.330 |
Why?
|
| Brain Infarction | 3 | 2013 | 28 | 0.330 |
Why?
|
| Lung Diseases | 1 | 2015 | 398 | 0.330 |
Why?
|
| Chromosome Deletion | 4 | 2025 | 653 | 0.330 |
Why?
|
| Treatment Outcome | 39 | 2026 | 12936 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 19 | 8 | 2010 | 54 | 0.330 |
Why?
|
| Disease | 4 | 2019 | 121 | 0.330 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2023 | 229 | 0.330 |
Why?
|
| Prealbumin | 2 | 2024 | 27 | 0.330 |
Why?
|
| Puberty | 2 | 2024 | 94 | 0.330 |
Why?
|
| Peripheral Vascular Diseases | 7 | 2011 | 73 | 0.330 |
Why?
|
| Glycemic Index | 1 | 2010 | 20 | 0.320 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 229 | 0.320 |
Why?
|
| Thrombosis | 4 | 2024 | 499 | 0.320 |
Why?
|
| Protein C | 3 | 2017 | 17 | 0.320 |
Why?
|
| Hypertriglyceridemia | 5 | 2012 | 117 | 0.310 |
Why?
|
| Molecular Epidemiology | 7 | 2017 | 139 | 0.310 |
Why?
|
| Eating | 3 | 2023 | 377 | 0.310 |
Why?
|
| Brain | 11 | 2023 | 3175 | 0.310 |
Why?
|
| Health Status | 4 | 2021 | 378 | 0.310 |
Why?
|
| Polymerase Chain Reaction | 20 | 2001 | 1447 | 0.310 |
Why?
|
| Periodontitis | 2 | 2023 | 19 | 0.310 |
Why?
|
| Biomedical Research | 3 | 2022 | 561 | 0.310 |
Why?
|
| Liver | 13 | 2021 | 1796 | 0.310 |
Why?
|
| Magnesium | 3 | 2017 | 114 | 0.310 |
Why?
|
| Pandemics | 5 | 2025 | 1118 | 0.310 |
Why?
|
| Extracellular Matrix Proteins | 4 | 2024 | 160 | 0.300 |
Why?
|
| Genomic Structural Variation | 2 | 2025 | 97 | 0.300 |
Why?
|
| Hemostasis | 5 | 2018 | 77 | 0.300 |
Why?
|
| Sodium-Glucose Transporter 1 | 3 | 2018 | 11 | 0.300 |
Why?
|
| Emergency Medical Services | 2 | 2024 | 352 | 0.300 |
Why?
|
| von Willebrand Diseases | 2 | 2025 | 54 | 0.300 |
Why?
|
| Retrospective Studies | 16 | 2025 | 17753 | 0.300 |
Why?
|
| Alternative Splicing | 5 | 2023 | 307 | 0.300 |
Why?
|
| HLA-DRB1 Chains | 2 | 2021 | 45 | 0.300 |
Why?
|
| ABO Blood-Group System | 4 | 2026 | 61 | 0.300 |
Why?
|
| RNA Splice Sites | 2 | 2023 | 92 | 0.300 |
Why?
|
| Macular Degeneration | 3 | 2023 | 86 | 0.300 |
Why?
|
| Analysis of Variance | 14 | 2017 | 928 | 0.300 |
Why?
|
| Selenoprotein P | 1 | 2009 | 3 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2014 | 87 | 0.300 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2023 | 245 | 0.300 |
Why?
|
| Glycoproteins | 5 | 2024 | 346 | 0.300 |
Why?
|
| Sorting Nexins | 2 | 2020 | 8 | 0.300 |
Why?
|
| Retinal Vein | 3 | 2015 | 5 | 0.300 |
Why?
|
| Alcohol Dehydrogenase | 4 | 2016 | 18 | 0.300 |
Why?
|
| Retinal Artery | 3 | 2015 | 16 | 0.290 |
Why?
|
| Receptors, Interleukin-6 | 3 | 2021 | 40 | 0.290 |
Why?
|
| Disease Progression | 13 | 2026 | 2200 | 0.290 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2024 | 544 | 0.290 |
Why?
|
| Age of Onset | 9 | 2021 | 592 | 0.290 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2009 | 38 | 0.290 |
Why?
|
| Qb-SNARE Proteins | 1 | 2008 | 6 | 0.290 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 7 | 1995 | 330 | 0.290 |
Why?
|
| Electronic Health Records | 4 | 2025 | 844 | 0.290 |
Why?
|
| Alcoholic Beverages | 2 | 2012 | 16 | 0.290 |
Why?
|
| Sphingolipids | 2 | 2020 | 47 | 0.280 |
Why?
|
| Chi-Square Distribution | 8 | 2017 | 563 | 0.280 |
Why?
|
| Deoxyglucose | 3 | 2019 | 41 | 0.280 |
Why?
|
| Serpins | 1 | 2008 | 34 | 0.280 |
Why?
|
| Mice | 30 | 2024 | 18301 | 0.280 |
Why?
|
| Phosphoproteins | 5 | 2023 | 448 | 0.280 |
Why?
|
| Amlodipine | 10 | 2015 | 21 | 0.280 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 6 | 2017 | 288 | 0.280 |
Why?
|
| Waist Circumference | 7 | 2021 | 94 | 0.280 |
Why?
|
| Family | 9 | 2022 | 589 | 0.280 |
Why?
|
| Epidemiology | 2 | 2019 | 9 | 0.280 |
Why?
|
| Chromosomes, Human, X | 5 | 2024 | 155 | 0.280 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 4 | 2018 | 35 | 0.280 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2008 | 22 | 0.280 |
Why?
|
| Presenilin-1 | 2 | 2025 | 51 | 0.270 |
Why?
|
| Coronary Stenosis | 1 | 2009 | 78 | 0.270 |
Why?
|
| Gene Deletion | 5 | 2019 | 767 | 0.270 |
Why?
|
| Infant | 20 | 2020 | 13352 | 0.270 |
Why?
|
| Hyperaldosteronism | 3 | 2022 | 17 | 0.270 |
Why?
|
| PPAR alpha | 1 | 2008 | 54 | 0.270 |
Why?
|
| Minority Groups | 2 | 2021 | 260 | 0.270 |
Why?
|
| RNA, Long Noncoding | 3 | 2023 | 218 | 0.270 |
Why?
|
| Body Fat Distribution | 4 | 2021 | 30 | 0.270 |
Why?
|
| Immunoassay | 3 | 2024 | 126 | 0.270 |
Why?
|
| Muscle Weakness | 2 | 2021 | 88 | 0.270 |
Why?
|
| Homeodomain Proteins | 5 | 2020 | 555 | 0.270 |
Why?
|
| Protein Sorting Signals | 4 | 1991 | 44 | 0.270 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 3 | 2019 | 40 | 0.270 |
Why?
|
| Aspirin | 1 | 2009 | 211 | 0.270 |
Why?
|
| Gene Dosage | 4 | 2020 | 435 | 0.270 |
Why?
|
| Comorbidity | 8 | 2021 | 1595 | 0.270 |
Why?
|
| Gene Expression | 11 | 2021 | 1481 | 0.260 |
Why?
|
| Genomic Imprinting | 4 | 2017 | 121 | 0.260 |
Why?
|
| Plasma | 3 | 2017 | 102 | 0.260 |
Why?
|
| Contrast Media | 3 | 2011 | 474 | 0.260 |
Why?
|
| Arthrogryposis | 2 | 2019 | 37 | 0.260 |
Why?
|
| Rhabdomyolysis | 2 | 2019 | 35 | 0.260 |
Why?
|
| Minnesota | 13 | 2018 | 178 | 0.260 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2008 | 80 | 0.260 |
Why?
|
| Longevity | 4 | 2021 | 178 | 0.260 |
Why?
|
| Apolipoprotein E4 | 3 | 2021 | 51 | 0.260 |
Why?
|
| Arterial Pressure | 3 | 2019 | 131 | 0.260 |
Why?
|
| Pregnancy | 8 | 2026 | 7512 | 0.260 |
Why?
|
| Datasets as Topic | 4 | 2021 | 99 | 0.260 |
Why?
|
| Hyperuricemia | 4 | 2014 | 39 | 0.260 |
Why?
|
| Microsatellite Repeats | 13 | 2019 | 204 | 0.260 |
Why?
|
| Renal Insufficiency | 2 | 2022 | 259 | 0.260 |
Why?
|
| Information Storage and Retrieval | 2 | 2021 | 65 | 0.260 |
Why?
|
| Metoprolol | 4 | 2019 | 21 | 0.260 |
Why?
|
| Proprotein Convertases | 7 | 2014 | 25 | 0.260 |
Why?
|
| Aortic Aneurysm, Thoracic | 4 | 2024 | 699 | 0.250 |
Why?
|
| Multigene Family | 6 | 2013 | 290 | 0.250 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2009 | 267 | 0.250 |
Why?
|
| Ubiquitin-Protein Ligases | 6 | 2021 | 354 | 0.250 |
Why?
|
| Thrombomodulin | 3 | 2006 | 18 | 0.250 |
Why?
|
| Malformations of Cortical Development | 2 | 2018 | 60 | 0.250 |
Why?
|
| Glucose Transport Proteins, Facilitative | 3 | 2018 | 22 | 0.250 |
Why?
|
| Tetraspanins | 2 | 2017 | 30 | 0.250 |
Why?
|
| Phospholipases A | 2 | 2006 | 31 | 0.250 |
Why?
|
| Essential Hypertension | 5 | 2018 | 12 | 0.250 |
Why?
|
| Lactase | 2 | 2024 | 42 | 0.250 |
Why?
|
| Fetal Hemoglobin | 2 | 2018 | 27 | 0.250 |
Why?
|
| Cyclooxygenase 2 | 1 | 2007 | 121 | 0.250 |
Why?
|
| Growth Disorders | 2 | 2020 | 181 | 0.240 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2015 | 108 | 0.240 |
Why?
|
| Erythropoiesis | 2 | 2016 | 39 | 0.240 |
Why?
|
| RNA-Binding Proteins | 6 | 2016 | 533 | 0.240 |
Why?
|
| Chromosome Aberrations | 3 | 2026 | 573 | 0.240 |
Why?
|
| Membrane Transport Proteins | 4 | 2024 | 180 | 0.240 |
Why?
|
| Anthropometry | 5 | 2016 | 187 | 0.240 |
Why?
|
| Oncogenic Viruses | 1 | 2026 | 22 | 0.240 |
Why?
|
| Amino Acid Substitution | 10 | 2018 | 405 | 0.240 |
Why?
|
| Minisatellite Repeats | 4 | 2003 | 43 | 0.240 |
Why?
|
| Nucleotides | 3 | 2021 | 88 | 0.240 |
Why?
|
| Premature Birth | 2 | 2025 | 428 | 0.240 |
Why?
|
| Vitamin D | 2 | 2018 | 194 | 0.230 |
Why?
|
| Signal Transduction | 9 | 2021 | 4686 | 0.230 |
Why?
|
| Laminin | 3 | 2017 | 66 | 0.230 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2026 | 38 | 0.230 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2019 | 99 | 0.230 |
Why?
|
| Exercise | 4 | 2019 | 892 | 0.230 |
Why?
|
| Intellectual Disability | 3 | 2020 | 1089 | 0.230 |
Why?
|
| Blood Pressure Determination | 4 | 2016 | 118 | 0.230 |
Why?
|
| 3' Untranslated Regions | 4 | 2017 | 154 | 0.230 |
Why?
|
| Carotid Stenosis | 2 | 2021 | 106 | 0.230 |
Why?
|
| Menopause | 5 | 2021 | 85 | 0.230 |
Why?
|
| Endophenotypes | 2 | 2022 | 14 | 0.230 |
Why?
|
| Adaptive Immunity | 1 | 2026 | 101 | 0.230 |
Why?
|
| Lisinopril | 8 | 2014 | 27 | 0.230 |
Why?
|
| Depression | 2 | 2018 | 1320 | 0.220 |
Why?
|
| Measles virus | 1 | 2025 | 16 | 0.220 |
Why?
|
| Antiporters | 5 | 2019 | 35 | 0.220 |
Why?
|
| Zebrafish | 7 | 2019 | 418 | 0.220 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2026 | 45 | 0.220 |
Why?
|
| Frameshift Mutation | 3 | 2015 | 200 | 0.220 |
Why?
|
| Biphenyl Compounds | 6 | 2019 | 75 | 0.220 |
Why?
|
| Calcium Channel Blockers | 7 | 2017 | 107 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 6 | 6 | 2025 | 137 | 0.220 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2022 | 33 | 0.220 |
Why?
|
| Rats, Inbred SHR | 7 | 2011 | 54 | 0.220 |
Why?
|
| Pulmonary Emphysema | 1 | 2026 | 96 | 0.220 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 45 | 0.220 |
Why?
|
| Bipolar Disorder | 3 | 2025 | 350 | 0.220 |
Why?
|
| Pharmacogenomic Testing | 3 | 2021 | 47 | 0.220 |
Why?
|
| Biological Transport | 8 | 2019 | 329 | 0.220 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 57 | 0.220 |
Why?
|
| Human Genome Project | 2 | 2013 | 54 | 0.220 |
Why?
|
| Cardiomyopathies | 4 | 2025 | 514 | 0.220 |
Why?
|
| Measles | 1 | 2025 | 39 | 0.220 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 338 | 0.220 |
Why?
|
| Infant, Newborn | 10 | 2019 | 8635 | 0.220 |
Why?
|
| Phospholipase C gamma | 2 | 2017 | 27 | 0.210 |
Why?
|
| Supervised Machine Learning | 1 | 2024 | 10 | 0.210 |
Why?
|
| Lectins, C-Type | 2 | 2024 | 71 | 0.210 |
Why?
|
| Nursing | 1 | 2004 | 9 | 0.210 |
Why?
|
| Kruppel-Like Transcription Factors | 3 | 2021 | 111 | 0.210 |
Why?
|
| Peroxidase | 2 | 2018 | 63 | 0.210 |
Why?
|
| Energy Intake | 3 | 2023 | 502 | 0.210 |
Why?
|
| Hypokalemia | 3 | 2016 | 41 | 0.210 |
Why?
|
| Patient-Centered Care | 1 | 2007 | 236 | 0.210 |
Why?
|
| Troponin I | 3 | 2021 | 122 | 0.210 |
Why?
|
| Databases, Factual | 5 | 2021 | 1240 | 0.210 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2014 | 64 | 0.210 |
Why?
|
| Forecasting | 4 | 2019 | 351 | 0.210 |
Why?
|
| Nursing Research | 1 | 2004 | 17 | 0.210 |
Why?
|
| Diabetes, Gestational | 1 | 2026 | 112 | 0.210 |
Why?
|
| Genetic Techniques | 3 | 2007 | 95 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2016 | 166 | 0.210 |
Why?
|
| United Kingdom | 4 | 2026 | 267 | 0.210 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 8 | 2016 | 52 | 0.210 |
Why?
|
| Apolipoprotein C-I | 2 | 2016 | 2 | 0.210 |
Why?
|
| Pyrrolidonecarboxylic Acid | 2 | 2014 | 6 | 0.210 |
Why?
|
| Circulating MicroRNA | 1 | 2024 | 12 | 0.210 |
Why?
|
| Drug Therapy, Combination | 11 | 2026 | 1173 | 0.210 |
Why?
|
| Benzothiadiazines | 1 | 2004 | 7 | 0.210 |
Why?
|
| Disease Outbreaks | 2 | 2023 | 311 | 0.210 |
Why?
|
| Clinical Laboratory Services | 1 | 2024 | 19 | 0.200 |
Why?
|
| Ultrasonography, Interventional | 1 | 2026 | 205 | 0.200 |
Why?
|
| N-Acetylgalactosaminyltransferases | 2 | 2022 | 12 | 0.200 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 289 | 0.200 |
Why?
|
| Myocytes, Cardiac | 4 | 2025 | 668 | 0.200 |
Why?
|
| Retinitis Pigmentosa | 2 | 2015 | 77 | 0.200 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2024 | 60 | 0.200 |
Why?
|
| Neurodegenerative Diseases | 2 | 2018 | 280 | 0.200 |
Why?
|
| Ventricular Remodeling | 3 | 2021 | 155 | 0.200 |
Why?
|
| Masks | 1 | 2024 | 34 | 0.200 |
Why?
|
| Megakaryocytes | 2 | 2021 | 40 | 0.200 |
Why?
|
| Acculturation | 1 | 2024 | 62 | 0.200 |
Why?
|
| Internationality | 2 | 2022 | 128 | 0.200 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2009 | 72 | 0.200 |
Why?
|
| Phosphorus | 2 | 2017 | 60 | 0.200 |
Why?
|
| Nucleotide Motifs | 3 | 2022 | 51 | 0.200 |
Why?
|
| Lysine | 2 | 2016 | 167 | 0.200 |
Why?
|
| Transcription, Genetic | 5 | 2021 | 1363 | 0.200 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2023 | 127 | 0.200 |
Why?
|
| Histone Deacetylases | 3 | 2020 | 130 | 0.200 |
Why?
|
| Chemokine CCL2 | 3 | 2009 | 112 | 0.200 |
Why?
|
| Ischemia | 4 | 2015 | 359 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 4 | 3 | 2019 | 53 | 0.200 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2015 | 130 | 0.200 |
Why?
|
| Loss of Function Mutation | 3 | 2021 | 177 | 0.200 |
Why?
|
| Partial Thromboplastin Time | 2 | 2014 | 55 | 0.200 |
Why?
|
| tau Proteins | 3 | 2023 | 257 | 0.200 |
Why?
|
| Poliovirus | 1 | 2023 | 47 | 0.200 |
Why?
|
| Anticholesteremic Agents | 1 | 2026 | 239 | 0.200 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2016 | 211 | 0.190 |
Why?
|
| Alcoholism | 2 | 2017 | 244 | 0.190 |
Why?
|
| Alanine Transaminase | 3 | 2012 | 153 | 0.190 |
Why?
|
| Apolipoprotein B-100 | 4 | 2016 | 36 | 0.190 |
Why?
|
| Serum Albumin | 3 | 2019 | 101 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2020 | 1267 | 0.190 |
Why?
|
| Cell Nucleus | 1 | 2025 | 556 | 0.190 |
Why?
|
| Mississippi | 11 | 2018 | 35 | 0.190 |
Why?
|
| Uromodulin | 4 | 2022 | 12 | 0.190 |
Why?
|
| Periodontal Diseases | 1 | 2023 | 31 | 0.190 |
Why?
|
| E-Selectin | 3 | 2006 | 38 | 0.190 |
Why?
|
| Nuclear Proteins | 4 | 2024 | 1211 | 0.190 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 235 | 0.190 |
Why?
|
| Drosophila melanogaster | 6 | 2019 | 789 | 0.190 |
Why?
|
| Bacteria | 3 | 2024 | 521 | 0.190 |
Why?
|
| Transposition of Great Vessels | 1 | 2024 | 118 | 0.190 |
Why?
|
| Vitamin B Complex | 1 | 2023 | 36 | 0.190 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2020 | 629 | 0.190 |
Why?
|
| Organic Cation Transport Proteins | 2 | 2019 | 13 | 0.190 |
Why?
|
| Leukemia | 1 | 2026 | 387 | 0.190 |
Why?
|
| Hepatitis | 1 | 2023 | 56 | 0.190 |
Why?
|
| Tobacco Use | 1 | 2022 | 29 | 0.190 |
Why?
|
| Patient Selection | 4 | 2010 | 729 | 0.190 |
Why?
|
| Influenza, Human | 2 | 2026 | 712 | 0.190 |
Why?
|
| Penetrance | 5 | 2023 | 107 | 0.190 |
Why?
|
| Telomere | 1 | 2024 | 219 | 0.190 |
Why?
|
| Cell Line | 11 | 2020 | 2552 | 0.190 |
Why?
|
| Heart Ventricles | 3 | 2021 | 749 | 0.190 |
Why?
|
| HEK293 Cells | 6 | 2025 | 801 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2011 | 77 | 0.180 |
Why?
|
| HIV-1 | 1 | 2026 | 490 | 0.180 |
Why?
|
| Receptors, Nicotinic | 2 | 2013 | 113 | 0.180 |
Why?
|
| Platelet Activation | 2 | 2021 | 64 | 0.180 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 350 | 0.180 |
Why?
|
| Statistics as Topic | 10 | 2011 | 242 | 0.180 |
Why?
|
| Platelet Count | 3 | 2017 | 139 | 0.180 |
Why?
|
| Endocrine System | 2 | 2020 | 18 | 0.180 |
Why?
|
| Steroids | 2 | 2022 | 170 | 0.180 |
Why?
|
| Amino Acid Sequence | 10 | 2017 | 2395 | 0.180 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2026 | 400 | 0.180 |
Why?
|
| GPI-Linked Proteins | 3 | 2019 | 110 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 1 | 5 | 2017 | 145 | 0.180 |
Why?
|
| Ion Channels | 6 | 2010 | 195 | 0.180 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2016 | 318 | 0.180 |
Why?
|
| Atrophy | 4 | 2020 | 247 | 0.180 |
Why?
|
| Diet, Mediterranean | 1 | 2022 | 18 | 0.180 |
Why?
|
| Hemostatics | 1 | 2022 | 58 | 0.180 |
Why?
|
| Pulmonary Edema | 1 | 2002 | 54 | 0.180 |
Why?
|
| Sodium-Bicarbonate Symporters | 2 | 2017 | 15 | 0.180 |
Why?
|
| Sequence Analysis | 3 | 2020 | 50 | 0.180 |
Why?
|
| Intubation, Intratracheal | 1 | 2024 | 212 | 0.180 |
Why?
|
| Mental Disorders | 2 | 2021 | 910 | 0.180 |
Why?
|
| Glycochenodeoxycholic Acid | 1 | 2021 | 7 | 0.180 |
Why?
|
| Ankle Brachial Index | 2 | 2012 | 40 | 0.180 |
Why?
|
| Fructosamine | 2 | 2019 | 10 | 0.180 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2015 | 80 | 0.180 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 2 | 2018 | 401 | 0.180 |
Why?
|
| Receptors, Dopamine D1 | 2 | 1998 | 29 | 0.180 |
Why?
|
| HLA-DQ alpha-Chains | 2 | 2021 | 15 | 0.180 |
Why?
|
| HIV Infections | 2 | 2026 | 2049 | 0.180 |
Why?
|
| Genome, Mitochondrial | 1 | 2021 | 27 | 0.170 |
Why?
|
| Rats | 11 | 2016 | 3370 | 0.170 |
Why?
|
| Tartronates | 1 | 2021 | 1 | 0.170 |
Why?
|
| Pregnancy Outcome | 1 | 2025 | 623 | 0.170 |
Why?
|
| Leukoencephalopathies | 2 | 2013 | 63 | 0.170 |
Why?
|
| Energy Metabolism | 6 | 2017 | 804 | 0.170 |
Why?
|
| Coffee | 1 | 2021 | 28 | 0.170 |
Why?
|
| Glucose Tolerance Test | 3 | 2018 | 198 | 0.170 |
Why?
|
| DNA, Satellite | 2 | 1992 | 15 | 0.170 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2021 | 72 | 0.170 |
Why?
|
| Homeostasis | 3 | 2019 | 712 | 0.170 |
Why?
|
| Tunica Media | 5 | 2010 | 15 | 0.170 |
Why?
|
| Microcirculation | 2 | 2013 | 104 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2026 | 570 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2025 | 487 | 0.170 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 419 | 0.170 |
Why?
|
| Hemoglobins | 3 | 2018 | 286 | 0.170 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type I | 2 | 2018 | 5 | 0.170 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2021 | 30 | 0.170 |
Why?
|
| GTPase-Activating Proteins | 2 | 2019 | 83 | 0.170 |
Why?
|
| Epidemiologic Methods | 6 | 2019 | 91 | 0.170 |
Why?
|
| Metabolic Diseases | 3 | 2019 | 143 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 421 | 0.170 |
Why?
|
| Methylamines | 1 | 2021 | 20 | 0.170 |
Why?
|
| Nuclear Family | 6 | 2001 | 51 | 0.170 |
Why?
|
| Tauopathies | 1 | 2022 | 72 | 0.170 |
Why?
|
| Memory, Short-Term | 1 | 2022 | 138 | 0.170 |
Why?
|
| Tomography, Optical Coherence | 1 | 2026 | 441 | 0.170 |
Why?
|
| Filtering Surgery | 1 | 2021 | 2 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 79 | 0.170 |
Why?
|
| Obesity, Abdominal | 4 | 2020 | 39 | 0.170 |
Why?
|
| Demography | 5 | 2014 | 237 | 0.170 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2021 | 49 | 0.170 |
Why?
|
| Neutrophils | 2 | 2017 | 371 | 0.170 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2021 | 58 | 0.170 |
Why?
|
| Echocardiography | 6 | 2019 | 1125 | 0.170 |
Why?
|
| Ovary | 2 | 2021 | 345 | 0.170 |
Why?
|
| Fertility | 2 | 2021 | 260 | 0.170 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2012 | 8 | 0.160 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2021 | 26 | 0.160 |
Why?
|
| Parents | 4 | 2014 | 1128 | 0.160 |
Why?
|
| Age Distribution | 5 | 2015 | 422 | 0.160 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 19 | 0.160 |
Why?
|
| Complement Factor H | 2 | 2013 | 24 | 0.160 |
Why?
|
| Kidney Function Tests | 5 | 2021 | 135 | 0.160 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 55 | 0.160 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 56 | 0.160 |
Why?
|
| Erythropoietin | 1 | 2021 | 102 | 0.160 |
Why?
|
| Interleukin-1 | 1 | 2021 | 130 | 0.160 |
Why?
|
| Healthy Lifestyle | 2 | 2021 | 33 | 0.160 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 154 | 0.160 |
Why?
|
| Hemochromatosis Protein | 2 | 2019 | 22 | 0.160 |
Why?
|
| Anorexia Nervosa | 1 | 2021 | 31 | 0.160 |
Why?
|
| Amyloid | 1 | 2021 | 72 | 0.160 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 549 | 0.160 |
Why?
|
| Losartan | 3 | 2015 | 36 | 0.160 |
Why?
|
| Eczema | 1 | 2020 | 35 | 0.160 |
Why?
|
| Wnt Proteins | 2 | 2018 | 191 | 0.160 |
Why?
|
| Sodium Channels | 5 | 2010 | 97 | 0.160 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 2 | 2018 | 5 | 0.160 |
Why?
|
| Galectins | 1 | 2020 | 24 | 0.160 |
Why?
|
| Vesicular Transport Proteins | 2 | 2019 | 138 | 0.160 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2011 | 56 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2021 | 412 | 0.160 |
Why?
|
| Muscle Proteins | 3 | 2019 | 401 | 0.160 |
Why?
|
| Dioxygenases | 4 | 2023 | 69 | 0.160 |
Why?
|
| DNA Repair | 2 | 2015 | 571 | 0.160 |
Why?
|
| Patient Care Planning | 1 | 2021 | 124 | 0.160 |
Why?
|
| Sulfonamides | 1 | 2002 | 296 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2021 | 56 | 0.160 |
Why?
|
| Lithium | 6 | 1987 | 66 | 0.160 |
Why?
|
| Carotid Artery, Internal | 2 | 2010 | 55 | 0.160 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 3 | 2016 | 44 | 0.160 |
Why?
|
| Women's Health | 2 | 2019 | 134 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2024 | 442 | 0.160 |
Why?
|
| Vitamin A | 3 | 1995 | 58 | 0.160 |
Why?
|
| beta-Globins | 1 | 2019 | 9 | 0.160 |
Why?
|
| Carnitine O-Palmitoyltransferase | 2 | 2021 | 26 | 0.160 |
Why?
|
| Brassicaceae | 1 | 2019 | 2 | 0.150 |
Why?
|
| Inbreeding Depression | 1 | 2019 | 2 | 0.150 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 72 | 0.150 |
Why?
|
| DNA Primers | 8 | 2006 | 599 | 0.150 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2020 | 47 | 0.150 |
Why?
|
| ATP-Binding Cassette Transporters | 4 | 2016 | 194 | 0.150 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2019 | 4 | 0.150 |
Why?
|
| Immune System | 1 | 2020 | 100 | 0.150 |
Why?
|
| Oxyhemoglobins | 1 | 2019 | 25 | 0.150 |
Why?
|
| Verbal Learning | 2 | 2022 | 67 | 0.150 |
Why?
|
| Ribonucleoproteins | 2 | 2017 | 56 | 0.150 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 151 | 0.150 |
Why?
|
| Syndrome | 7 | 2017 | 1155 | 0.150 |
Why?
|
| Arabs | 2 | 2016 | 29 | 0.150 |
Why?
|
| Duffy Blood-Group System | 2 | 2009 | 9 | 0.150 |
Why?
|
| Protein Interaction Maps | 3 | 2017 | 93 | 0.150 |
Why?
|
| Molecular Biology | 2 | 1997 | 66 | 0.150 |
Why?
|
| Metalloendopeptidases | 2 | 2017 | 101 | 0.150 |
Why?
|
| Cloud Computing | 2 | 2019 | 15 | 0.150 |
Why?
|
| Inflammasomes | 1 | 2021 | 154 | 0.150 |
Why?
|
| Body Weight | 8 | 2010 | 987 | 0.150 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2020 | 73 | 0.150 |
Why?
|
| Receptor, Angiotensin, Type 1 | 5 | 2020 | 55 | 0.150 |
Why?
|
| Histidine | 2 | 2020 | 69 | 0.150 |
Why?
|
| Decision Making | 1 | 2025 | 726 | 0.150 |
Why?
|
| Sodium-Glucose Transport Proteins | 1 | 2019 | 3 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2011 | 143 | 0.150 |
Why?
|
| High-Temperature Requirement A Serine Peptidase 1 | 1 | 2019 | 2 | 0.150 |
Why?
|
| Oxidative Stress | 3 | 2020 | 791 | 0.150 |
Why?
|
| Receptor, Notch3 | 1 | 2019 | 12 | 0.150 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2019 | 2 | 0.150 |
Why?
|
| Cerebellar Ataxia | 1 | 2019 | 61 | 0.150 |
Why?
|
| Risk-Taking | 1 | 2019 | 96 | 0.150 |
Why?
|
| Organizational Policy | 1 | 2019 | 50 | 0.150 |
Why?
|
| KCNQ1 Potassium Channel | 3 | 2014 | 12 | 0.150 |
Why?
|
| Learning | 1 | 2022 | 356 | 0.150 |
Why?
|
| Optic Atrophy | 2 | 2016 | 42 | 0.150 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 232 | 0.150 |
Why?
|
| Matrix Metalloproteinase 3 | 2 | 2010 | 17 | 0.150 |
Why?
|
| RNA, Messenger | 8 | 2023 | 2550 | 0.150 |
Why?
|
| Pravastatin | 3 | 2009 | 22 | 0.150 |
Why?
|
| Viral Vaccines | 1 | 2022 | 324 | 0.140 |
Why?
|
| Protein Precursors | 3 | 2021 | 140 | 0.140 |
Why?
|
| Adenosine Triphosphatases | 2 | 2017 | 189 | 0.140 |
Why?
|
| 2-Aminoadipate Transaminase | 1 | 2018 | 1 | 0.140 |
Why?
|
| Memory | 2 | 2024 | 314 | 0.140 |
Why?
|
| Loss of Heterozygosity | 2 | 2024 | 123 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2011 | 142 | 0.140 |
Why?
|
| Bestrophins | 1 | 2018 | 14 | 0.140 |
Why?
|
| Symporters | 1 | 2019 | 80 | 0.140 |
Why?
|
| Proteoglycans | 4 | 2022 | 77 | 0.140 |
Why?
|
| Metformin | 2 | 2018 | 174 | 0.140 |
Why?
|
| Hyperlipidemias | 2 | 2004 | 185 | 0.140 |
Why?
|
| Drug Resistance | 2 | 2017 | 242 | 0.140 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 35 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2020 | 230 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2023 | 356 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 354 | 0.140 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2019 | 38 | 0.140 |
Why?
|
| Thyrotropin | 1 | 2018 | 50 | 0.140 |
Why?
|
| Immunity, Innate | 2 | 2021 | 406 | 0.140 |
Why?
|
| Solute Carrier Family 12, Member 1 | 1 | 2018 | 1 | 0.140 |
Why?
|
| Mutagenesis | 4 | 2021 | 324 | 0.140 |
Why?
|
| Community Participation | 1 | 2019 | 42 | 0.140 |
Why?
|
| Lactic Acid | 2 | 2018 | 149 | 0.140 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2011 | 135 | 0.140 |
Why?
|
| Receptors, Adrenergic | 1 | 1998 | 15 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2017 | 214 | 0.140 |
Why?
|
| Atrial Function | 1 | 2018 | 17 | 0.140 |
Why?
|
| Chloride Channels | 2 | 2015 | 55 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 182 | 0.140 |
Why?
|
| Oxidoreductases | 2 | 2020 | 105 | 0.140 |
Why?
|
| Registries | 4 | 2023 | 1634 | 0.140 |
Why?
|
| Atrioventricular Node | 1 | 2018 | 16 | 0.140 |
Why?
|
| Developmental Disabilities | 4 | 2016 | 781 | 0.140 |
Why?
|
| Receptors, Interleukin | 1 | 2018 | 36 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Synthase | 1 | 2018 | 2 | 0.140 |
Why?
|
| Thyroid Hormones | 1 | 2018 | 54 | 0.140 |
Why?
|
| Electrophysiological Phenomena | 1 | 2018 | 56 | 0.140 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2018 | 31 | 0.140 |
Why?
|
| Erythroid Cells | 1 | 2018 | 23 | 0.140 |
Why?
|
| Leukoaraiosis | 2 | 2009 | 4 | 0.140 |
Why?
|
| Trehalose | 2 | 2018 | 21 | 0.140 |
Why?
|
| Glioma | 1 | 2023 | 494 | 0.140 |
Why?
|
| Golgi Apparatus | 2 | 2016 | 92 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 5 | 2019 | 21 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 1999 | 111 | 0.140 |
Why?
|
| Doxazosin | 4 | 2012 | 27 | 0.140 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 34 | 0.140 |
Why?
|
| Receptors, Odorant | 1 | 2018 | 33 | 0.140 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 231 | 0.140 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 170 | 0.140 |
Why?
|
| Retinal Vessels | 3 | 2013 | 48 | 0.140 |
Why?
|
| rab GTP-Binding Proteins | 2 | 2015 | 52 | 0.130 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 2 | 2017 | 81 | 0.130 |
Why?
|
| Lung | 1 | 2026 | 1535 | 0.130 |
Why?
|
| Isoleucine | 2 | 2018 | 24 | 0.130 |
Why?
|
| Models, Biological | 4 | 2018 | 1371 | 0.130 |
Why?
|
| GTP Phosphohydrolases | 1 | 2019 | 155 | 0.130 |
Why?
|
| Protein Phosphatase 1 | 2 | 2015 | 53 | 0.130 |
Why?
|
| Retinal Dehydrogenase | 1 | 2017 | 18 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2017 | 1071 | 0.130 |
Why?
|
| Colon | 1 | 2000 | 373 | 0.130 |
Why?
|
| Fibrosis | 3 | 2026 | 429 | 0.130 |
Why?
|
| Gain of Function Mutation | 1 | 2018 | 115 | 0.130 |
Why?
|
| Zebrafish Proteins | 1 | 2019 | 133 | 0.130 |
Why?
|
| Ion Channel Gating | 1 | 2018 | 119 | 0.130 |
Why?
|
| Likelihood Functions | 3 | 2009 | 116 | 0.130 |
Why?
|
| Particle Size | 6 | 2014 | 135 | 0.130 |
Why?
|
| Hypertension, Renal | 2 | 2008 | 30 | 0.130 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 2 | 2014 | 38 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 2 | 2012 | 300 | 0.130 |
Why?
|
| Hemizygote | 1 | 2017 | 13 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 164 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1586 | 0.130 |
Why?
|
| Arterioles | 2 | 2015 | 37 | 0.130 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2017 | 28 | 0.130 |
Why?
|
| Cluster Analysis | 3 | 2014 | 414 | 0.130 |
Why?
|
| Phospholipase A2 Inhibitors | 1 | 2016 | 2 | 0.130 |
Why?
|
| Population Growth | 2 | 2013 | 5 | 0.130 |
Why?
|
| Son of Sevenless Proteins | 1 | 2016 | 6 | 0.130 |
Why?
|
| Artificial Intelligence | 3 | 2014 | 369 | 0.130 |
Why?
|
| Africa | 5 | 2020 | 135 | 0.130 |
Why?
|
| Double-Blind Method | 8 | 2016 | 1626 | 0.130 |
Why?
|
| Vascular Stiffness | 2 | 2017 | 76 | 0.130 |
Why?
|
| Liddle Syndrome | 1 | 2016 | 4 | 0.130 |
Why?
|
| Maternal Exposure | 1 | 2018 | 150 | 0.130 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 82 | 0.130 |
Why?
|
| Benzaldehydes | 1 | 2016 | 13 | 0.130 |
Why?
|
| Polymorphism, Restriction Fragment Length | 7 | 2000 | 132 | 0.130 |
Why?
|
| Homocysteine | 2 | 2008 | 116 | 0.120 |
Why?
|
| Louisiana | 8 | 2011 | 137 | 0.120 |
Why?
|
| Paired Box Transcription Factors | 2 | 2014 | 72 | 0.120 |
Why?
|
| Clusterin | 1 | 2016 | 11 | 0.120 |
Why?
|
| HMGA2 Protein | 2 | 2014 | 12 | 0.120 |
Why?
|
| Platelet Aggregation | 1 | 2017 | 100 | 0.120 |
Why?
|
| Tropomyosin | 1 | 2016 | 26 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 227 | 0.120 |
Why?
|
| Aorta | 3 | 2020 | 521 | 0.120 |
Why?
|
| Severity of Illness Index | 9 | 2021 | 3061 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 73 | 0.120 |
Why?
|
| Thioredoxins | 1 | 2016 | 28 | 0.120 |
Why?
|
| Leucine | 2 | 2018 | 259 | 0.120 |
Why?
|
| Oximes | 1 | 2016 | 56 | 0.120 |
Why?
|
| Limit of Detection | 1 | 2016 | 74 | 0.120 |
Why?
|
| Fibroblast Growth Factor 8 | 1 | 2016 | 9 | 0.120 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2016 | 18 | 0.120 |
Why?
|
| Sudden Infant Death | 1 | 2016 | 36 | 0.120 |
Why?
|
| Hypotension | 1 | 2018 | 187 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 732 | 0.120 |
Why?
|
| Protein Isoforms | 5 | 2009 | 423 | 0.120 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2014 | 101 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2024 | 705 | 0.120 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2016 | 49 | 0.120 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 262 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2024 | 289 | 0.120 |
Why?
|
| Causality | 1 | 2016 | 89 | 0.120 |
Why?
|
| Reference Values | 6 | 2016 | 676 | 0.120 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2016 | 35 | 0.120 |
Why?
|
| Entropy | 2 | 2007 | 30 | 0.120 |
Why?
|
| Receptors, Cytokine | 1 | 2016 | 65 | 0.120 |
Why?
|
| RNA Interference | 2 | 2015 | 491 | 0.120 |
Why?
|
| Communicable Diseases | 1 | 2018 | 155 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2013 | 13 | 0.120 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2017 | 77 | 0.120 |
Why?
|
| Monte Carlo Method | 3 | 2008 | 98 | 0.120 |
Why?
|
| Megalencephaly | 1 | 2016 | 59 | 0.120 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Vascular Calcification | 2 | 2016 | 70 | 0.120 |
Why?
|
| Adipogenesis | 2 | 2015 | 82 | 0.120 |
Why?
|
| Tenascin | 1 | 2016 | 33 | 0.120 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2015 | 5 | 0.120 |
Why?
|
| Genes, Recessive | 1 | 2016 | 193 | 0.120 |
Why?
|
| Transposases | 1 | 2016 | 44 | 0.120 |
Why?
|
| Glucose Transporter Type 2 | 2 | 2013 | 6 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 4 | 2020 | 378 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 903 | 0.120 |
Why?
|
| Brain Edema | 1 | 2016 | 66 | 0.120 |
Why?
|
| Receptors, Neurokinin-3 | 1 | 2015 | 1 | 0.120 |
Why?
|
| Genetic Load | 1 | 2015 | 5 | 0.120 |
Why?
|
| Microglia | 1 | 2017 | 147 | 0.110 |
Why?
|
| Immune System Diseases | 1 | 2016 | 58 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 523 | 0.110 |
Why?
|
| Kidney Tubules | 1 | 2015 | 76 | 0.110 |
Why?
|
| Stroke Volume | 3 | 2024 | 541 | 0.110 |
Why?
|
| NADP Transhydrogenase, AB-Specific | 1 | 2015 | 4 | 0.110 |
Why?
|
| Myocardial Revascularization | 2 | 2021 | 100 | 0.110 |
Why?
|
| Granulocytes | 2 | 2021 | 69 | 0.110 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2016 | 59 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 78 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2017 | 645 | 0.110 |
Why?
|
| TRPM Cation Channels | 1 | 2015 | 12 | 0.110 |
Why?
|
| Health Planning Councils | 1 | 2015 | 2 | 0.110 |
Why?
|
| Mucin-1 | 1 | 2015 | 32 | 0.110 |
Why?
|
| Myocardium | 2 | 2019 | 852 | 0.110 |
Why?
|
| Phospholipase D | 1 | 2015 | 8 | 0.110 |
Why?
|
| Biological Evolution | 4 | 2015 | 222 | 0.110 |
Why?
|
| Apolipoprotein A-V | 6 | 2014 | 21 | 0.110 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2015 | 31 | 0.110 |
Why?
|
| HMGN1 Protein | 1 | 2015 | 2 | 0.110 |
Why?
|
| Cadmium | 1 | 2015 | 33 | 0.110 |
Why?
|
| Histidine Ammonia-Lyase | 1 | 2015 | 4 | 0.110 |
Why?
|
| Coatomer Protein | 1 | 2015 | 28 | 0.110 |
Why?
|
| Tobacco Use Disorder | 2 | 2013 | 87 | 0.110 |
Why?
|
| Autoantigens | 1 | 2015 | 97 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 3 | 2018 | 334 | 0.110 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2020 | 74 | 0.110 |
Why?
|
| Sickle Cell Trait | 1 | 2014 | 10 | 0.110 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2015 | 45 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 2015 | 152 | 0.110 |
Why?
|
| Codon | 1 | 1995 | 93 | 0.110 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2015 | 21 | 0.110 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 76 | 0.110 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 2 | 2019 | 242 | 0.110 |
Why?
|
| Conserved Sequence | 2 | 2012 | 277 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2016 | 197 | 0.110 |
Why?
|
| De Lange Syndrome | 1 | 2015 | 44 | 0.110 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 1 | 1 | 2014 | 13 | 0.110 |
Why?
|
| Mutation Rate | 1 | 2015 | 68 | 0.110 |
Why?
|
| HLA-B27 Antigen | 1 | 2014 | 5 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 219 | 0.110 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2014 | 15 | 0.110 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 235 | 0.110 |
Why?
|
| Embolism | 1 | 2015 | 38 | 0.110 |
Why?
|
| Educational Status | 3 | 2022 | 279 | 0.110 |
Why?
|
| Indican | 1 | 2014 | 8 | 0.110 |
Why?
|
| Phosphoglucomutase | 1 | 2014 | 7 | 0.110 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2014 | 35 | 0.110 |
Why?
|
| Optic Atrophies, Hereditary | 1 | 2014 | 16 | 0.110 |
Why?
|
| Receptors, Adrenergic, beta-3 | 3 | 2005 | 14 | 0.110 |
Why?
|
| Arthritis | 1 | 2015 | 85 | 0.110 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2014 | 9 | 0.110 |
Why?
|
| Creatine | 1 | 2014 | 37 | 0.110 |
Why?
|
| Finland | 8 | 2015 | 46 | 0.100 |
Why?
|
| Hypogonadism | 2 | 2015 | 299 | 0.100 |
Why?
|
| Scoliosis | 1 | 2016 | 147 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 10 | 3 | 2011 | 67 | 0.100 |
Why?
|
| Phosphotransferases | 1 | 2014 | 33 | 0.100 |
Why?
|
| Global Health | 1 | 2019 | 626 | 0.100 |
Why?
|
| Alopecia | 1 | 2014 | 41 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2014 | 363 | 0.100 |
Why?
|
| Spasms, Infantile | 1 | 2016 | 166 | 0.100 |
Why?
|
| Cities | 2 | 2024 | 51 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 386 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta-1 | 4 | 2019 | 13 | 0.100 |
Why?
|
| Calpain | 3 | 2010 | 42 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 324 | 0.100 |
Why?
|
| Cerebral Cortex | 3 | 2016 | 445 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2014 | 229 | 0.100 |
Why?
|
| RNA, Transfer | 1 | 2014 | 57 | 0.100 |
Why?
|
| Amyloidosis | 1 | 2015 | 70 | 0.100 |
Why?
|
| Cation Transport Proteins | 1 | 2014 | 100 | 0.100 |
Why?
|
| Hydroxyurea | 1 | 2014 | 89 | 0.100 |
Why?
|
| Bone Diseases, Developmental | 1 | 2014 | 64 | 0.100 |
Why?
|
| Hypothalamus | 1 | 2015 | 206 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 429 | 0.100 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2013 | 38 | 0.100 |
Why?
|
| Cells, Cultured | 5 | 2018 | 2885 | 0.100 |
Why?
|
| RNA Precursors | 1 | 2013 | 42 | 0.100 |
Why?
|
| Fetal Proteins | 1 | 2013 | 11 | 0.100 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2014 | 50 | 0.100 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 13 | 0.100 |
Why?
|
| Macrophages | 1 | 2018 | 667 | 0.100 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 2 | 2012 | 29 | 0.100 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2015 | 227 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 1306 | 0.100 |
Why?
|
| Coronary Artery Bypass | 3 | 2013 | 515 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 98 | 0.100 |
Why?
|
| Alanine | 3 | 2009 | 160 | 0.100 |
Why?
|
| Cellular Senescence | 1 | 2015 | 217 | 0.100 |
Why?
|
| Facies | 3 | 2020 | 157 | 0.100 |
Why?
|
| Heat-Shock Proteins | 1 | 2014 | 174 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2009 | 466 | 0.100 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2013 | 67 | 0.100 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2013 | 26 | 0.100 |
Why?
|
| Retinal Diseases | 2 | 2013 | 142 | 0.100 |
Why?
|
| Fructokinases | 1 | 2013 | 2 | 0.100 |
Why?
|
| Glucose Transporter Type 5 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2015 | 167 | 0.100 |
Why?
|
| Turkey | 3 | 2018 | 69 | 0.100 |
Why?
|
| Dental Caries Susceptibility | 1 | 2012 | 1 | 0.100 |
Why?
|
| beta 2-Microglobulin | 1 | 2013 | 35 | 0.100 |
Why?
|
| Cattle | 2 | 2024 | 501 | 0.100 |
Why?
|
| Chromosomes | 2 | 2011 | 120 | 0.100 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 263 | 0.100 |
Why?
|
| Epilepsy, Generalized | 1 | 2013 | 63 | 0.100 |
Why?
|
| Marfan Syndrome | 1 | 2015 | 147 | 0.100 |
Why?
|
| Dental Caries | 1 | 2012 | 11 | 0.100 |
Why?
|
| Lipocalins | 1 | 2013 | 30 | 0.100 |
Why?
|
| Asthma | 1 | 2021 | 922 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 786 | 0.090 |
Why?
|
| Cystatin C | 3 | 2023 | 70 | 0.090 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2012 | 11 | 0.090 |
Why?
|
| Microvessels | 1 | 2013 | 58 | 0.090 |
Why?
|
| Receptors, Thrombin | 1 | 2012 | 12 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 981 | 0.090 |
Why?
|
| G-Protein-Coupled Receptor Kinase 4 | 1 | 2012 | 2 | 0.090 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2013 | 41 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2014 | 204 | 0.090 |
Why?
|
| Language Development Disorders | 1 | 2014 | 177 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2016 | 292 | 0.090 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 2602 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 357 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 46 | 0.090 |
Why?
|
| Prothrombin Time | 1 | 2012 | 36 | 0.090 |
Why?
|
| Epilepsy | 1 | 2020 | 876 | 0.090 |
Why?
|
| High Mobility Group Proteins | 1 | 2012 | 33 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 119 | 0.090 |
Why?
|
| Sensitivity and Specificity | 7 | 2013 | 2085 | 0.090 |
Why?
|
| T-Box Domain Proteins | 1 | 2013 | 123 | 0.090 |
Why?
|
| Aspartate Aminotransferases | 1 | 2012 | 80 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 4738 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 116 | 0.090 |
Why?
|
| Hypotension, Orthostatic | 1 | 2012 | 20 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2026 | 354 | 0.090 |
Why?
|
| Brachial Artery | 3 | 2007 | 34 | 0.090 |
Why?
|
| Protein Transport | 3 | 2020 | 366 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 362 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 2017 | 308 | 0.090 |
Why?
|
| Cadherins | 3 | 2018 | 182 | 0.090 |
Why?
|
| Probability | 6 | 2011 | 306 | 0.090 |
Why?
|
| Cholesterol, Dietary | 1 | 1991 | 49 | 0.090 |
Why?
|
| Abnormalities, Multiple | 2 | 2014 | 963 | 0.090 |
Why?
|
| Blood Cell Count | 2 | 2025 | 65 | 0.090 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2011 | 14 | 0.090 |
Why?
|
| Germ Cells | 3 | 2021 | 201 | 0.090 |
Why?
|
| Body Composition | 3 | 2009 | 545 | 0.090 |
Why?
|
| Research Support as Topic | 1 | 2012 | 61 | 0.090 |
Why?
|
| Academies and Institutes | 1 | 2012 | 81 | 0.090 |
Why?
|
| INDEL Mutation | 2 | 2022 | 93 | 0.090 |
Why?
|
| Workflow | 3 | 2017 | 144 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2013 | 221 | 0.090 |
Why?
|
| Adiponectin | 1 | 2012 | 123 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2012 | 93 | 0.090 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2013 | 177 | 0.090 |
Why?
|
| Crossing Over, Genetic | 1 | 2011 | 53 | 0.090 |
Why?
|
| Wnt Signaling Pathway | 1 | 2012 | 223 | 0.090 |
Why?
|
| Sterol Esterase | 1 | 2011 | 20 | 0.090 |
Why?
|
| Drinking Behavior | 1 | 2011 | 8 | 0.080 |
Why?
|
| Hybrid Cells | 2 | 2008 | 77 | 0.080 |
Why?
|
| Ultrasonography | 6 | 2010 | 943 | 0.080 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2024 | 95 | 0.080 |
Why?
|
| Adipokines | 3 | 2016 | 119 | 0.080 |
Why?
|
| Statistics, Nonparametric | 4 | 2009 | 423 | 0.080 |
Why?
|
| G-Protein-Coupled Receptor Kinase 5 | 1 | 2011 | 3 | 0.080 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 3 | 2017 | 82 | 0.080 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2011 | 49 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 1618 | 0.080 |
Why?
|
| Politics | 1 | 2012 | 62 | 0.080 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 25 | 0.080 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2011 | 7 | 0.080 |
Why?
|
| Overweight | 1 | 2014 | 387 | 0.080 |
Why?
|
| Integrin beta3 | 1 | 2011 | 27 | 0.080 |
Why?
|
| Drosophila Proteins | 1 | 2016 | 718 | 0.080 |
Why?
|
| Forced Expiratory Volume | 2 | 2026 | 178 | 0.080 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2011 | 47 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2015 | 787 | 0.080 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2008 | 63 | 0.080 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2011 | 83 | 0.080 |
Why?
|
| Caffeine | 1 | 2011 | 66 | 0.080 |
Why?
|
| Serine | 2 | 2001 | 161 | 0.080 |
Why?
|
| North Carolina | 4 | 2018 | 48 | 0.080 |
Why?
|
| Calcium | 3 | 2011 | 1010 | 0.080 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2011 | 60 | 0.080 |
Why?
|
| Body Constitution | 4 | 2003 | 42 | 0.080 |
Why?
|
| Vasculitis | 1 | 2011 | 47 | 0.080 |
Why?
|
| Liver Diseases | 2 | 2012 | 385 | 0.080 |
Why?
|
| Aorta, Thoracic | 2 | 2012 | 530 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2017 | 623 | 0.080 |
Why?
|
| Oregon | 2 | 2026 | 10 | 0.080 |
Why?
|
| Cell Cycle Proteins | 4 | 2016 | 710 | 0.080 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2010 | 50 | 0.080 |
Why?
|
| Apolipoprotein A-II | 4 | 2008 | 5 | 0.080 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 53 | 0.080 |
Why?
|
| Lymphocytes | 2 | 2009 | 344 | 0.080 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2010 | 6 | 0.080 |
Why?
|
| Verapamil | 3 | 2017 | 43 | 0.080 |
Why?
|
| Checkpoint Kinase 2 | 3 | 2021 | 37 | 0.080 |
Why?
|
| Hypolipoproteinemias | 2 | 2006 | 4 | 0.080 |
Why?
|
| Genes, X-Linked | 2 | 2024 | 59 | 0.080 |
Why?
|
| ERG1 Potassium Channel | 2 | 2026 | 6 | 0.080 |
Why?
|
| Medical History Taking | 2 | 2020 | 107 | 0.080 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2010 | 53 | 0.080 |
Why?
|
| Genetic Code | 3 | 2014 | 22 | 0.080 |
Why?
|
| Random Allocation | 3 | 2000 | 409 | 0.080 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2010 | 12 | 0.080 |
Why?
|
| Diet Records | 1 | 2010 | 69 | 0.080 |
Why?
|
| Rest | 1 | 2010 | 64 | 0.080 |
Why?
|
| Biostatistics | 1 | 2010 | 10 | 0.080 |
Why?
|
| Leukocyte Common Antigens | 1 | 2010 | 84 | 0.080 |
Why?
|
| Self Report | 1 | 2013 | 554 | 0.080 |
Why?
|
| Receptors, Gastrointestinal Hormone | 1 | 2010 | 10 | 0.080 |
Why?
|
| American Heart Association | 2 | 2022 | 343 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2011 | 179 | 0.080 |
Why?
|
| Biological Transport, Active | 3 | 2006 | 70 | 0.080 |
Why?
|
| Glypicans | 1 | 2010 | 36 | 0.080 |
Why?
|
| Chromatin | 2 | 2025 | 499 | 0.080 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 62 | 0.080 |
Why?
|
| Spinal Dysraphism | 1 | 2013 | 261 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 126 | 0.080 |
Why?
|
| Apolipoprotein E3 | 1 | 2009 | 8 | 0.080 |
Why?
|
| Nitric Oxide | 2 | 2022 | 471 | 0.080 |
Why?
|
| Cardiovascular System | 1 | 2010 | 97 | 0.080 |
Why?
|
| Ankle | 2 | 2007 | 30 | 0.080 |
Why?
|
| Mucoproteins | 1 | 2009 | 10 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 13 | 4 | 2014 | 48 | 0.070 |
Why?
|
| Folic Acid | 1 | 2011 | 269 | 0.070 |
Why?
|
| Threonine | 1 | 2009 | 62 | 0.070 |
Why?
|
| Angiopoietin-like Proteins | 3 | 2017 | 15 | 0.070 |
Why?
|
| Aortic Diseases | 1 | 2011 | 190 | 0.070 |
Why?
|
| Blood Coagulation Factors | 1 | 2009 | 30 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2009 | 23 | 0.070 |
Why?
|
| Hyperhomocysteinemia | 2 | 2006 | 37 | 0.070 |
Why?
|
| Cerebral Ventricles | 1 | 2009 | 80 | 0.070 |
Why?
|
| Apolipoprotein C-II | 3 | 1995 | 4 | 0.070 |
Why?
|
| Motor Activity | 1 | 2012 | 489 | 0.070 |
Why?
|
| Seizures | 1 | 2014 | 890 | 0.070 |
Why?
|
| Maryland | 3 | 2018 | 39 | 0.070 |
Why?
|
| Calcium Channels | 1 | 2009 | 143 | 0.070 |
Why?
|
| Chromosomes, Human, 4-5 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Chromosomes, Human, 6-12 and X | 1 | 2008 | 1 | 0.070 |
Why?
|
| Machine Learning | 2 | 2025 | 387 | 0.070 |
Why?
|
| Pressoreceptors | 1 | 2008 | 9 | 0.070 |
Why?
|
| Moyamoya Disease | 1 | 2009 | 41 | 0.070 |
Why?
|
| Glycation End Products, Advanced | 2 | 2019 | 25 | 0.070 |
Why?
|
| Community-Based Participatory Research | 1 | 2009 | 65 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 633 | 0.070 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2008 | 12 | 0.070 |
Why?
|
| Gene Amplification | 1 | 1989 | 219 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 226 | 0.070 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Heart Atria | 2 | 2022 | 343 | 0.070 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2008 | 4 | 0.070 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2008 | 8 | 0.070 |
Why?
|
| Netherlands | 4 | 2012 | 55 | 0.070 |
Why?
|
| Histones | 1 | 2012 | 541 | 0.070 |
Why?
|
| Asparagine | 2 | 2018 | 22 | 0.070 |
Why?
|
| Mannose-Binding Lectin | 1 | 2008 | 5 | 0.070 |
Why?
|
| NADPH Oxidases | 2 | 2020 | 109 | 0.070 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2008 | 45 | 0.070 |
Why?
|
| Monosomy | 1 | 2007 | 24 | 0.070 |
Why?
|
| Hemochromatosis | 1 | 2008 | 44 | 0.070 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2007 | 3 | 0.070 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2007 | 5 | 0.070 |
Why?
|
| Postprandial Period | 2 | 2015 | 93 | 0.070 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2008 | 105 | 0.070 |
Why?
|
| Weight Gain | 2 | 2008 | 393 | 0.070 |
Why?
|
| Nutritional Sciences | 1 | 2008 | 67 | 0.070 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2007 | 48 | 0.070 |
Why?
|
| CRISPR-Cas Systems | 2 | 2024 | 317 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2021 | 157 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 109 | 0.070 |
Why?
|
| Coronary Angiography | 5 | 2016 | 450 | 0.070 |
Why?
|
| Bisoprolol | 2 | 2019 | 7 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 20 | 2 | 2008 | 31 | 0.070 |
Why?
|
| Genes, Neoplasm | 2 | 2014 | 80 | 0.070 |
Why?
|
| Acyltransferases | 3 | 2014 | 63 | 0.070 |
Why?
|
| Community Health Services | 1 | 2008 | 86 | 0.060 |
Why?
|
| Discriminant Analysis | 2 | 2012 | 21 | 0.060 |
Why?
|
| Apolipoprotein E2 | 3 | 2016 | 16 | 0.060 |
Why?
|
| Protective Factors | 2 | 2018 | 91 | 0.060 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 2 | 2019 | 31 | 0.060 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2008 | 127 | 0.060 |
Why?
|
| Protein-Arginine N-Methyltransferases | 2 | 2023 | 34 | 0.060 |
Why?
|
| Actins | 1 | 2009 | 321 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 420 | 0.060 |
Why?
|
| Serine C-Palmitoyltransferase | 2 | 2017 | 18 | 0.060 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 4697 | 0.060 |
Why?
|
| Organic Anion Transporters | 2 | 2018 | 23 | 0.060 |
Why?
|
| Physical Chromosome Mapping | 2 | 2021 | 55 | 0.060 |
Why?
|
| Drosophila | 3 | 2019 | 739 | 0.060 |
Why?
|
| Rats, Inbred WKY | 4 | 2009 | 43 | 0.060 |
Why?
|
| Desmoglein 2 | 1 | 2026 | 4 | 0.060 |
Why?
|
| Gallbladder Diseases | 1 | 2006 | 25 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 639 | 0.060 |
Why?
|
| Lamin Type A | 1 | 2026 | 14 | 0.060 |
Why?
|
| Desmoplakins | 1 | 2026 | 12 | 0.060 |
Why?
|
| Galactosyltransferases | 1 | 2026 | 8 | 0.060 |
Why?
|
| Diterpenes | 3 | 1995 | 33 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2008 | 224 | 0.060 |
Why?
|
| Osteoarthritis | 1 | 2008 | 105 | 0.060 |
Why?
|
| Spirometry | 1 | 2026 | 92 | 0.060 |
Why?
|
| Growth Differentiation Factor 5 | 2 | 2021 | 3 | 0.060 |
Why?
|
| Gene Editing | 2 | 2021 | 238 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2019 | 3819 | 0.060 |
Why?
|
| California | 1 | 2026 | 127 | 0.060 |
Why?
|
| Markov Chains | 2 | 2013 | 101 | 0.060 |
Why?
|
| Co-Repressor Proteins | 2 | 2019 | 38 | 0.060 |
Why?
|
| Vital Capacity | 1 | 2026 | 81 | 0.060 |
Why?
|
| Caspase 9 | 2 | 2019 | 76 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2014 | 304 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2008 | 358 | 0.060 |
Why?
|
| Fibrillin-1 | 2 | 2016 | 59 | 0.060 |
Why?
|
| WNK Lysine-Deficient Protein Kinase 1 | 1 | 2005 | 14 | 0.060 |
Why?
|
| Diabetic Retinopathy | 1 | 2007 | 75 | 0.060 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2005 | 37 | 0.060 |
Why?
|
| Universities | 1 | 2026 | 125 | 0.060 |
Why?
|
| Respiratory Function Tests | 1 | 2026 | 222 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2007 | 365 | 0.060 |
Why?
|
| DNA-Directed DNA Polymerase | 3 | 2012 | 87 | 0.060 |
Why?
|
| Cytochrome P-450 CYP11B2 | 1 | 2005 | 3 | 0.060 |
Why?
|
| Database Management Systems | 1 | 2005 | 26 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2026 | 164 | 0.060 |
Why?
|
| Sulfotransferases | 2 | 2015 | 28 | 0.060 |
Why?
|
| Glycine | 3 | 2006 | 156 | 0.060 |
Why?
|
| Protein Subunits | 2 | 2007 | 157 | 0.060 |
Why?
|
| Islets of Langerhans | 2 | 2016 | 163 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2019 | 248 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2024 | 523 | 0.060 |
Why?
|
| Interferon Regulatory Factors | 2 | 2017 | 46 | 0.050 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2026 | 159 | 0.050 |
Why?
|
| Massachusetts | 2 | 2017 | 122 | 0.050 |
Why?
|
| North America | 2 | 2016 | 255 | 0.050 |
Why?
|
| Livestock | 1 | 2024 | 12 | 0.050 |
Why?
|
| Farmers | 1 | 2024 | 13 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2016 | 128 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 431 | 0.050 |
Why?
|
| Luciferases | 2 | 2002 | 127 | 0.050 |
Why?
|
| Puberty, Delayed | 1 | 2024 | 5 | 0.050 |
Why?
|
| Ecology | 1 | 2004 | 11 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2017 | 1445 | 0.050 |
Why?
|
| Birds | 1 | 2024 | 48 | 0.050 |
Why?
|
| Oocytes | 2 | 2021 | 283 | 0.050 |
Why?
|
| Influenza in Birds | 1 | 2024 | 27 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2011 | 468 | 0.050 |
Why?
|
| Thiazides | 1 | 2024 | 5 | 0.050 |
Why?
|
| Oxidation-Reduction | 2 | 2020 | 436 | 0.050 |
Why?
|
| Epidemiological Monitoring | 1 | 2024 | 69 | 0.050 |
Why?
|
| Puberty, Precocious | 1 | 2024 | 25 | 0.050 |
Why?
|
| Subtilisins | 2 | 2014 | 11 | 0.050 |
Why?
|
| Asymptomatic Diseases | 2 | 2016 | 77 | 0.050 |
Why?
|
| K562 Cells | 1 | 2024 | 97 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2002 | 65 | 0.050 |
Why?
|
| Nodal Protein | 1 | 2024 | 28 | 0.050 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2024 | 64 | 0.050 |
Why?
|
| Anaerobiosis | 1 | 2023 | 14 | 0.050 |
Why?
|
| Binding Sites | 2 | 2017 | 1133 | 0.050 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 338 | 0.050 |
Why?
|
| Nonlinear Dynamics | 1 | 2024 | 54 | 0.050 |
Why?
|
| Angiotensin II | 2 | 2018 | 131 | 0.050 |
Why?
|
| Fathers | 1 | 2004 | 74 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2024 | 78 | 0.050 |
Why?
|
| Proteolysis | 2 | 2017 | 200 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2003 | 43 | 0.050 |
Why?
|
| Leptin | 3 | 2000 | 218 | 0.050 |
Why?
|
| Valine | 2 | 2018 | 110 | 0.050 |
Why?
|
| Gene Conversion | 2 | 2000 | 14 | 0.050 |
Why?
|
| Plasmalogens | 1 | 2023 | 7 | 0.050 |
Why?
|
| Aminoisobutyric Acids | 1 | 2023 | 7 | 0.050 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2023 | 10 | 0.050 |
Why?
|
| Airway Management | 1 | 2024 | 52 | 0.050 |
Why?
|
| Laboratories | 1 | 2024 | 81 | 0.050 |
Why?
|
| Metabolism | 1 | 2023 | 45 | 0.050 |
Why?
|
| Aminopeptidases | 1 | 2023 | 15 | 0.050 |
Why?
|
| Milk | 1 | 2024 | 109 | 0.050 |
Why?
|
| Neuropeptide Y | 2 | 2000 | 34 | 0.050 |
Why?
|
| Mannose | 1 | 2023 | 25 | 0.050 |
Why?
|
| DNA Damage | 2 | 2021 | 511 | 0.050 |
Why?
|
| Glycerol | 1 | 2023 | 78 | 0.050 |
Why?
|
| Lysophospholipids | 1 | 2003 | 45 | 0.050 |
Why?
|
| Radiography | 2 | 2018 | 743 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2024 | 138 | 0.050 |
Why?
|
| Stents | 1 | 2009 | 799 | 0.050 |
Why?
|
| Base Composition | 1 | 2002 | 66 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2023 | 72 | 0.050 |
Why?
|
| Forearm | 1 | 2003 | 39 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2003 | 94 | 0.050 |
Why?
|
| Caveolin 1 | 1 | 2022 | 51 | 0.050 |
Why?
|
| Trans-Activators | 2 | 2017 | 697 | 0.050 |
Why?
|
| Diet, Vegetarian | 1 | 2022 | 7 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 370 | 0.050 |
Why?
|
| Models, Theoretical | 2 | 2024 | 362 | 0.050 |
Why?
|
| Altitude | 1 | 2002 | 22 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2002 | 97 | 0.050 |
Why?
|
| Immunologic Tests | 1 | 2022 | 18 | 0.050 |
Why?
|
| Urinalysis | 1 | 2023 | 72 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2022 | 11 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 236 | 0.050 |
Why?
|
| Reproduction | 2 | 2015 | 210 | 0.050 |
Why?
|
| Oklahoma | 1 | 2002 | 15 | 0.050 |
Why?
|
| Capillary Permeability | 1 | 2002 | 73 | 0.050 |
Why?
|
| HapMap Project | 2 | 2012 | 13 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 1129 | 0.050 |
Why?
|
| Factor XIIIa | 1 | 2002 | 2 | 0.050 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2024 | 566 | 0.050 |
Why?
|
| Plants | 1 | 2022 | 49 | 0.040 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2015 | 167 | 0.040 |
Why?
|
| Brain Diseases | 1 | 2005 | 299 | 0.040 |
Why?
|
| Anoctamins | 1 | 2021 | 13 | 0.040 |
Why?
|
| Virulence | 1 | 2022 | 268 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2019 | 1064 | 0.040 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2023 | 115 | 0.040 |
Why?
|
| Myotonic Dystrophy | 2 | 1992 | 73 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2013 | 89 | 0.040 |
Why?
|
| Drinking | 1 | 2021 | 27 | 0.040 |
Why?
|
| Protein Conformation | 2 | 2014 | 732 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 509 | 0.040 |
Why?
|
| Menopause, Premature | 1 | 2021 | 6 | 0.040 |
Why?
|
| Hippurates | 1 | 2021 | 7 | 0.040 |
Why?
|
| Inositol | 1 | 2021 | 13 | 0.040 |
Why?
|
| Indians, North American | 1 | 2002 | 71 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 26 | 0.040 |
Why?
|
| DNA Demethylation | 1 | 2021 | 11 | 0.040 |
Why?
|
| Catechols | 1 | 2021 | 9 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 1419 | 0.040 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2021 | 26 | 0.040 |
Why?
|
| Sulfates | 1 | 2021 | 31 | 0.040 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2021 | 37 | 0.040 |
Why?
|
| Healthy Aging | 1 | 2021 | 13 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2008 | 294 | 0.040 |
Why?
|
| Oxalates | 1 | 2021 | 22 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2021 | 27 | 0.040 |
Why?
|
| Kynurenine | 1 | 2021 | 24 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2021 | 15 | 0.040 |
Why?
|
| Elasticity | 3 | 2007 | 97 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1545 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2021 | 49 | 0.040 |
Why?
|
| Mothers | 1 | 2004 | 388 | 0.040 |
Why?
|
| Population Density | 1 | 2021 | 31 | 0.040 |
Why?
|
| Methylhistidines | 1 | 2020 | 7 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2016 | 849 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2013 | 2065 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2024 | 589 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2001 | 64 | 0.040 |
Why?
|
| Vasoconstriction | 1 | 2021 | 94 | 0.040 |
Why?
|
| GATA5 Transcription Factor | 1 | 2020 | 2 | 0.040 |
Why?
|
| Iceland | 3 | 2016 | 12 | 0.040 |
Why?
|
| Biotransformation | 1 | 2001 | 54 | 0.040 |
Why?
|
| Phospholipase C beta | 1 | 2020 | 8 | 0.040 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2021 | 50 | 0.040 |
Why?
|
| Antigens, Human Platelet | 1 | 2000 | 6 | 0.040 |
Why?
|
| France | 2 | 1994 | 90 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 43 | 0.040 |
Why?
|
| Cytochrome P450 Family 4 | 1 | 2020 | 5 | 0.040 |
Why?
|
| Chromans | 1 | 2020 | 8 | 0.040 |
Why?
|
| alpha Karyopherins | 1 | 2020 | 7 | 0.040 |
Why?
|
| Ornithine | 1 | 2020 | 31 | 0.040 |
Why?
|
| Adipose Tissue | 3 | 2010 | 502 | 0.040 |
Why?
|
| Transfection | 1 | 2002 | 962 | 0.040 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2020 | 32 | 0.040 |
Why?
|
| Tripartite Motif Proteins | 1 | 2020 | 24 | 0.040 |
Why?
|
| Propionates | 1 | 2020 | 31 | 0.040 |
Why?
|
| Sequence Deletion | 2 | 2017 | 516 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2021 | 98 | 0.040 |
Why?
|
| Phospholipases A2, Calcium-Independent | 2 | 2012 | 19 | 0.040 |
Why?
|
| Hypoxia | 1 | 2002 | 247 | 0.040 |
Why?
|
| Tibial Arteries | 1 | 2020 | 8 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 435 | 0.040 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2020 | 41 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2010 | 2326 | 0.040 |
Why?
|
| Mood Disorders | 1 | 2021 | 129 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 48 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 117 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2021 | 77 | 0.040 |
Why?
|
| Vitamin E | 1 | 2020 | 65 | 0.040 |
Why?
|
| Amino Acid Transport Systems, Neutral | 1 | 2020 | 14 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 905 | 0.040 |
Why?
|
| False Positive Reactions | 3 | 2010 | 143 | 0.040 |
Why?
|
| Acetylation | 1 | 2020 | 190 | 0.040 |
Why?
|
| DNA Helicases | 2 | 2012 | 239 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 321 | 0.040 |
Why?
|
| Survival Rate | 2 | 2017 | 2114 | 0.040 |
Why?
|
| LIM Domain Proteins | 1 | 2020 | 64 | 0.040 |
Why?
|
| Hypothalamic Diseases | 1 | 2020 | 40 | 0.040 |
Why?
|
| China | 5 | 2004 | 278 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 137 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 314 | 0.040 |
Why?
|
| Androsterone | 1 | 2019 | 2 | 0.040 |
Why?
|
| Mitochondria, Heart | 1 | 2020 | 58 | 0.040 |
Why?
|
| Poisson Distribution | 2 | 2012 | 50 | 0.040 |
Why?
|
| Receptors, Vasopressin | 1 | 2019 | 13 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 975 | 0.040 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 2 | 2015 | 30 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2021 | 221 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2019 | 7 | 0.040 |
Why?
|
| Receptor, Insulin | 1 | 1999 | 65 | 0.040 |
Why?
|
| Uncoupling Protein 2 | 2 | 2010 | 13 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2465 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 279 | 0.040 |
Why?
|
| Sexual Maturation | 2 | 2009 | 45 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 1483 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2019 | 36 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 1999 | 58 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2023 | 448 | 0.040 |
Why?
|
| DNA Replication | 1 | 2021 | 355 | 0.040 |
Why?
|
| Ankyrins | 1 | 2020 | 96 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2013 | 50 | 0.040 |
Why?
|
| Twin Studies as Topic | 1 | 1999 | 14 | 0.040 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2019 | 28 | 0.040 |
Why?
|
| ADAMTS9 Protein | 1 | 2018 | 1 | 0.040 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2018 | 10 | 0.040 |
Why?
|
| Peroxidases | 1 | 2019 | 29 | 0.040 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2018 | 9 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2021 | 308 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 1999 | 38 | 0.040 |
Why?
|
| Recombinases | 1 | 2019 | 28 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 255 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 116 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 394 | 0.040 |
Why?
|
| RNA Splicing Factors | 1 | 2019 | 51 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 172 | 0.040 |
Why?
|
| Solute Carrier Family 12, Member 3 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2018 | 24 | 0.040 |
Why?
|
| Radioimmunoassay | 2 | 2013 | 82 | 0.040 |
Why?
|
| Recurrence | 2 | 2013 | 1489 | 0.040 |
Why?
|
| gamma-Globins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 1998 | 16 | 0.040 |
Why?
|
| Volatile Organic Compounds | 1 | 2018 | 13 | 0.030 |
Why?
|
| Body Patterning | 1 | 2019 | 122 | 0.030 |
Why?
|
| COS Cells | 1 | 2018 | 253 | 0.030 |
Why?
|
| Receptors, Angiotensin | 1 | 1998 | 20 | 0.030 |
Why?
|
| Biophysical Phenomena | 1 | 2018 | 39 | 0.030 |
Why?
|
| Sampling Studies | 1 | 1998 | 76 | 0.030 |
Why?
|
| Erythritol | 1 | 2018 | 4 | 0.030 |
Why?
|
| Denmark | 2 | 2010 | 28 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2018 | 235 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2018 | 96 | 0.030 |
Why?
|
| Siloxanes | 1 | 2017 | 2 | 0.030 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2018 | 37 | 0.030 |
Why?
|
| Sex Distribution | 3 | 2006 | 318 | 0.030 |
Why?
|
| Blood Buffy Coat | 1 | 2017 | 2 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2017 | 6 | 0.030 |
Why?
|
| Trust | 1 | 2019 | 91 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2017 | 8 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2018 | 71 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 664 | 0.030 |
Why?
|
| Amidohydrolases | 1 | 2018 | 21 | 0.030 |
Why?
|
| Receptors, Leptin | 2 | 2013 | 40 | 0.030 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2017 | 17 | 0.030 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 402 | 0.030 |
Why?
|
| Georgia | 1 | 2017 | 46 | 0.030 |
Why?
|
| Permeability | 1 | 2018 | 126 | 0.030 |
Why?
|
| Information Services | 1 | 2017 | 23 | 0.030 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2017 | 13 | 0.030 |
Why?
|
| Florida | 1 | 2017 | 73 | 0.030 |
Why?
|
| Kallikreins | 1 | 2017 | 28 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2017 | 37 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 1998 | 39 | 0.030 |
Why?
|
| Reaction Time | 1 | 2018 | 152 | 0.030 |
Why?
|
| Diet, Atherogenic | 2 | 2001 | 14 | 0.030 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2018 | 75 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2017 | 50 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2004 | 919 | 0.030 |
Why?
|
| Minichromosome Maintenance Complex Component 6 | 1 | 2017 | 5 | 0.030 |
Why?
|
| Health Equity | 1 | 2019 | 78 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 546 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2017 | 50 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2002 | 457 | 0.030 |
Why?
|
| Psychology | 1 | 2017 | 62 | 0.030 |
Why?
|
| Epithelium | 1 | 2018 | 335 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2018 | 276 | 0.030 |
Why?
|
| Uterus | 1 | 2021 | 541 | 0.030 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 1 | 2017 | 1 | 0.030 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2017 | 31 | 0.030 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 9 | 0.030 |
Why?
|
| ADAMTS Proteins | 1 | 2017 | 10 | 0.030 |
Why?
|
| NADPH Oxidase 4 | 1 | 2017 | 13 | 0.030 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2017 | 10 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2017 | 48 | 0.030 |
Why?
|
| Equipment Design | 1 | 2019 | 512 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 521 | 0.030 |
Why?
|
| Diethylamines | 1 | 2016 | 4 | 0.030 |
Why?
|
| Somatomedins | 1 | 2017 | 33 | 0.030 |
Why?
|
| Embryonic Development | 1 | 2019 | 200 | 0.030 |
Why?
|
| Nitriles | 1 | 2017 | 163 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2017 | 148 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2017 | 68 | 0.030 |
Why?
|
| Education | 1 | 2017 | 112 | 0.030 |
Why?
|
| Histone Code | 1 | 2017 | 46 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2017 | 42 | 0.030 |
Why?
|
| Deoxyribonuclease HindIII | 1 | 1996 | 4 | 0.030 |
Why?
|
| Sulfides | 1 | 2016 | 21 | 0.030 |
Why?
|
| Amiloride | 1 | 2016 | 29 | 0.030 |
Why?
|
| Genetics | 1 | 1997 | 24 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 270 | 0.030 |
Why?
|
| Ribonucleosides | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 506 | 0.030 |
Why?
|
| Xanthines | 1 | 2016 | 10 | 0.030 |
Why?
|
| Phlebotomy | 1 | 1996 | 20 | 0.030 |
Why?
|
| DCC Receptor | 1 | 2016 | 5 | 0.030 |
Why?
|
| Mean Platelet Volume | 1 | 2016 | 4 | 0.030 |
Why?
|
| Singapore | 2 | 2013 | 16 | 0.030 |
Why?
|
| Skinfold Thickness | 2 | 2009 | 34 | 0.030 |
Why?
|
| Erythrocyte Indices | 1 | 2016 | 12 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2016 | 3 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 11 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2016 | 62 | 0.030 |
Why?
|
| Blood Preservation | 1 | 1996 | 29 | 0.030 |
Why?
|
| Neurons | 2 | 2016 | 1979 | 0.030 |
Why?
|
| Government Agencies | 1 | 2016 | 12 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 2016 | 79 | 0.030 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2016 | 22 | 0.030 |
Why?
|
| Indoles | 1 | 2017 | 200 | 0.030 |
Why?
|
| Patient Admission | 1 | 2017 | 185 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2016 | 21 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 197 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 387 | 0.030 |
Why?
|
| Muscles | 1 | 2016 | 197 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2016 | 55 | 0.030 |
Why?
|
| Hematocrit | 1 | 2016 | 104 | 0.030 |
Why?
|
| Cathepsin C | 1 | 2015 | 1 | 0.030 |
Why?
|
| Epinephrine | 1 | 2017 | 150 | 0.030 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 1 | 2016 | 22 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 293 | 0.030 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 17 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2000 | 254 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2017 | 114 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2016 | 32 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2016 | 222 | 0.030 |
Why?
|
| Dominican Republic | 1 | 2015 | 15 | 0.030 |
Why?
|
| Data Mining | 1 | 2016 | 68 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 282 | 0.030 |
Why?
|
| Venules | 1 | 2015 | 28 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2015 | 54 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 199 | 0.030 |
Why?
|
| Myelin P2 Protein | 1 | 2015 | 10 | 0.030 |
Why?
|
| New York City | 1 | 2015 | 59 | 0.030 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2015 | 21 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2017 | 223 | 0.030 |
Why?
|
| Suppression, Genetic | 1 | 2015 | 38 | 0.030 |
Why?
|
| Hominidae | 1 | 1995 | 29 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 179 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 61 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 2015 | 89 | 0.030 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 133 | 0.030 |
Why?
|
| Progestins | 1 | 2015 | 39 | 0.030 |
Why?
|
| Fibrillins | 1 | 2015 | 27 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 223 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 109 | 0.030 |
Why?
|
| Lung Volume Measurements | 1 | 2015 | 72 | 0.030 |
Why?
|
| Diploidy | 1 | 2015 | 40 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 526 | 0.030 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 17 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 195 | 0.030 |
Why?
|
| Scotland | 1 | 2015 | 24 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2015 | 18 | 0.030 |
Why?
|
| Protein Folding | 1 | 2016 | 214 | 0.030 |
Why?
|
| Microscopy, Acoustic | 1 | 2015 | 15 | 0.030 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 216 | 0.030 |
Why?
|
| ATP Binding Cassette Transporter 1 | 2 | 2006 | 16 | 0.030 |
Why?
|
| Amides | 1 | 2015 | 81 | 0.030 |
Why?
|
| Position-Specific Scoring Matrices | 1 | 2014 | 8 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 731 | 0.030 |
Why?
|
| Gestational Age | 1 | 2019 | 1224 | 0.030 |
Why?
|
| Claudin-5 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Exonucleases | 1 | 2015 | 27 | 0.030 |
Why?
|
| Methods | 2 | 2003 | 95 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 256 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2015 | 142 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2009 | 202 | 0.030 |
Why?
|
| Environment | 3 | 2010 | 149 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 183 | 0.030 |
Why?
|
| Sulfonylurea Receptors | 1 | 2014 | 12 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2014 | 27 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 263 | 0.030 |
Why?
|
| Embryo, Nonmammalian | 1 | 2015 | 141 | 0.030 |
Why?
|
| Receptors, GABA-B | 1 | 2014 | 10 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 224 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 1995 | 177 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 137 | 0.030 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2014 | 5 | 0.030 |
Why?
|
| Vision Tests | 1 | 2014 | 26 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 407 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2016 | 403 | 0.030 |
Why?
|
| Potassium Channels | 1 | 2015 | 154 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2014 | 26 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2014 | 77 | 0.030 |
Why?
|
| Oligonucleotides | 3 | 2002 | 94 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 179 | 0.030 |
Why?
|
| Gene Library | 1 | 2015 | 212 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2015 | 291 | 0.030 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2014 | 32 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2014 | 57 | 0.030 |
Why?
|
| Chromosome Segregation | 1 | 2014 | 68 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2015 | 81 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 258 | 0.030 |
Why?
|
| Cerebrum | 1 | 2014 | 32 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2010 | 272 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2015 | 208 | 0.030 |
Why?
|
| Peptides | 1 | 2017 | 708 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2014 | 92 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 335 | 0.030 |
Why?
|
| Lentivirus | 1 | 2014 | 80 | 0.030 |
Why?
|
| Neurologic Manifestations | 1 | 2013 | 4 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2015 | 200 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2014 | 122 | 0.030 |
Why?
|
| Cotinine | 1 | 2013 | 25 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 408 | 0.030 |
Why?
|
| Blindness, Cortical | 1 | 2013 | 15 | 0.030 |
Why?
|
| Apoproteins | 1 | 1993 | 11 | 0.030 |
Why?
|
| Neural Conduction | 1 | 2013 | 82 | 0.030 |
Why?
|
| Intrinsically Disordered Proteins | 1 | 2014 | 63 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 463 | 0.020 |
Why?
|
| PAX3 Transcription Factor | 1 | 2013 | 26 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 184 | 0.020 |
Why?
|
| X Chromosome | 1 | 2014 | 327 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2016 | 262 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 1993 | 44 | 0.020 |
Why?
|
| Endoribonucleases | 1 | 2014 | 87 | 0.020 |
Why?
|
| Population Control | 1 | 2013 | 4 | 0.020 |
Why?
|
| Axons | 1 | 2016 | 386 | 0.020 |
Why?
|
| Coronary Thrombosis | 1 | 1993 | 33 | 0.020 |
Why?
|
| MEF2 Transcription Factors | 1 | 2013 | 34 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2013 | 20 | 0.020 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2013 | 10 | 0.020 |
Why?
|
| Zinc Finger Protein Gli3 | 1 | 2013 | 6 | 0.020 |
Why?
|
| Integrin alpha4 | 1 | 2013 | 12 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 209 | 0.020 |
Why?
|
| Dentition, Permanent | 1 | 2012 | 1 | 0.020 |
Why?
|
| DMF Index | 1 | 2012 | 2 | 0.020 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2013 | 10 | 0.020 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2013 | 34 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 323 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2000 | 2026 | 0.020 |
Why?
|
| Health Surveys | 1 | 2014 | 261 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 47 | 0.020 |
Why?
|
| Vascular Patency | 1 | 1993 | 185 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2013 | 79 | 0.020 |
Why?
|
| Fusion Regulatory Protein 1, Heavy Chain | 1 | 2012 | 4 | 0.020 |
Why?
|
| Amino Acid Transport Systems, Basic | 1 | 2012 | 11 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 251 | 0.020 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2013 | 77 | 0.020 |
Why?
|
| GATA2 Transcription Factor | 1 | 2013 | 46 | 0.020 |
Why?
|
| Inhibin-beta Subunits | 1 | 2012 | 18 | 0.020 |
Why?
|
| Epidemiologic Factors | 1 | 1992 | 9 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2013 | 352 | 0.020 |
Why?
|
| Support Vector Machine | 1 | 2012 | 27 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 716 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2012 | 34 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1997 | 713 | 0.020 |
Why?
|
| Inhibins | 1 | 2012 | 82 | 0.020 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 1 | 2012 | 18 | 0.020 |
Why?
|
| Genetic Fitness | 1 | 2012 | 34 | 0.020 |
Why?
|
| Pakistan | 1 | 2012 | 99 | 0.020 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2012 | 9 | 0.020 |
Why?
|
| Adolescent Development | 1 | 2012 | 29 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2012 | 13 | 0.020 |
Why?
|
| DNA Primase | 1 | 2012 | 24 | 0.020 |
Why?
|
| DNA Polymerase gamma | 1 | 2012 | 19 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 62 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 12 | 0.020 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2012 | 44 | 0.020 |
Why?
|
| Cerebellum | 1 | 2016 | 441 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 40 | 0.020 |
Why?
|
| Ribosomes | 1 | 2012 | 123 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2012 | 35 | 0.020 |
Why?
|
| Exodeoxyribonucleases | 1 | 2012 | 52 | 0.020 |
Why?
|
| Multilevel Analysis | 1 | 2011 | 9 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2012 | 82 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2011 | 28 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2012 | 147 | 0.020 |
Why?
|
| Africa, Western | 1 | 2011 | 15 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 199 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 46 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1992 | 315 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2012 | 150 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 451 | 0.020 |
Why?
|
| Nicotine | 1 | 2012 | 115 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1205 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 480 | 0.020 |
Why?
|
| Synapses | 1 | 2015 | 425 | 0.020 |
Why?
|
| Autopsy | 1 | 2011 | 111 | 0.020 |
Why?
|
| Asia | 1 | 2011 | 124 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 613 | 0.020 |
Why?
|
| X Chromosome Inactivation | 1 | 2011 | 59 | 0.020 |
Why?
|
| Kringles | 1 | 2011 | 3 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 2007 | 341 | 0.020 |
Why?
|
| Fetus | 1 | 2014 | 568 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2014 | 523 | 0.020 |
Why?
|
| Interleukin-11 | 1 | 2010 | 7 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 96 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 189 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 50 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 192 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 89 | 0.020 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 160 | 0.020 |
Why?
|
| Sequence Tagged Sites | 1 | 1990 | 26 | 0.020 |
Why?
|
| Genes, BRCA2 | 1 | 2010 | 49 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 327 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2010 | 53 | 0.020 |
Why?
|
| Genes, BRCA1 | 1 | 2010 | 60 | 0.020 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2010 | 7 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1928 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2010 | 15 | 0.020 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2010 | 11 | 0.020 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 23 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 195 | 0.020 |
Why?
|
| MARVEL Domain-Containing Proteins | 1 | 2010 | 2 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1990 | 121 | 0.020 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2011 | 65 | 0.020 |
Why?
|
| Base Pairing | 1 | 2010 | 40 | 0.020 |
Why?
|
| Integrin beta Chains | 1 | 2010 | 8 | 0.020 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2010 | 19 | 0.020 |
Why?
|
| Pan troglodytes | 2 | 2002 | 70 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 38 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 84 | 0.020 |
Why?
|
| Hypobetalipoproteinemias | 1 | 1989 | 3 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 241 | 0.020 |
Why?
|
| Adenylyl Cyclases | 1 | 2010 | 45 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 94 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2010 | 106 | 0.020 |
Why?
|
| Incretins | 1 | 2010 | 26 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 569 | 0.020 |
Why?
|
| Restriction Mapping | 2 | 2004 | 167 | 0.020 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2009 | 6 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1882 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2009 | 112 | 0.020 |
Why?
|
| Taq Polymerase | 1 | 1989 | 7 | 0.020 |
Why?
|
| Blood Donors | 2 | 1986 | 58 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 172 | 0.020 |
Why?
|
| Animals, Congenic | 1 | 2008 | 7 | 0.020 |
Why?
|
| Rats, Inbred BN | 1 | 2008 | 16 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 450 | 0.020 |
Why?
|
| Concept Formation | 1 | 2008 | 27 | 0.020 |
Why?
|
| Carboxylesterase | 1 | 1988 | 6 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2009 | 241 | 0.020 |
Why?
|
| Movement Disorders | 1 | 2011 | 218 | 0.020 |
Why?
|
| Epitopes | 1 | 1990 | 324 | 0.020 |
Why?
|
| Antioxidants | 1 | 2011 | 331 | 0.020 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2008 | 3 | 0.020 |
Why?
|
| Protein Binding | 1 | 1992 | 1652 | 0.020 |
Why?
|
| Apoprotein(a) | 3 | 1994 | 6 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2008 | 80 | 0.020 |
Why?
|
| Recombination, Genetic | 2 | 2000 | 422 | 0.020 |
Why?
|
| Hepatolenticular Degeneration | 1 | 1988 | 36 | 0.020 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 1 | 2007 | 1 | 0.020 |
Why?
|
| Animal Feed | 1 | 2008 | 82 | 0.020 |
Why?
|
| Ferritins | 1 | 2008 | 104 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2009 | 171 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2008 | 58 | 0.020 |
Why?
|
| American Hospital Association | 1 | 2007 | 3 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2007 | 25 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2007 | 11 | 0.020 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type III | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 1339 | 0.020 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2007 | 28 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2010 | 1021 | 0.020 |
Why?
|
| Voltage-Gated Sodium Channels | 1 | 2007 | 12 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2007 | 39 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2007 | 134 | 0.020 |
Why?
|
| Peer Review, Research | 1 | 2007 | 45 | 0.020 |
Why?
|
| Hirschsprung Disease | 1 | 2007 | 39 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2007 | 59 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2008 | 197 | 0.020 |
Why?
|
| RGS Proteins | 1 | 2006 | 47 | 0.020 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 10 | 0.020 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2006 | 64 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2007 | 109 | 0.020 |
Why?
|
| Guanidinoacetate N-Methyltransferase | 1 | 2006 | 8 | 0.020 |
Why?
|
| Vitamin D-Binding Protein | 1 | 1986 | 5 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2006 | 26 | 0.020 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2006 | 19 | 0.020 |
Why?
|
| Mass Screening | 2 | 2003 | 822 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2003 | 1013 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2006 | 65 | 0.010 |
Why?
|
| Mexico | 2 | 2000 | 190 | 0.010 |
Why?
|
| Solubility | 1 | 2006 | 117 | 0.010 |
Why?
|
| Japan | 2 | 1996 | 161 | 0.010 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 157 | 0.010 |
Why?
|
| Ankle Joint | 1 | 2005 | 33 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2008 | 711 | 0.010 |
Why?
|
| Iron | 1 | 2008 | 304 | 0.010 |
Why?
|
| Physicians' Offices | 1 | 2005 | 10 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2005 | 76 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2009 | 905 | 0.010 |
Why?
|
| Lipolysis | 1 | 2005 | 83 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 12 | 0.010 |
Why?
|
| Geography | 1 | 2004 | 114 | 0.010 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2006 | 156 | 0.010 |
Why?
|
| Viral Structural Proteins | 1 | 2004 | 39 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 1319 | 0.010 |
Why?
|
| Coronavirus | 1 | 2004 | 27 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 221 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 470 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2004 | 155 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 223 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2007 | 229 | 0.010 |
Why?
|
| Receptor, trkB | 1 | 2003 | 22 | 0.010 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 1983 | 4 | 0.010 |
Why?
|
| Estrogens | 1 | 2006 | 434 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2004 | 182 | 0.010 |
Why?
|
| Normal Distribution | 1 | 2003 | 19 | 0.010 |
Why?
|
| Thrombophilia | 1 | 2003 | 41 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 421 | 0.010 |
Why?
|
| Government Programs | 1 | 2003 | 11 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2003 | 85 | 0.010 |
Why?
|
| Proline | 1 | 2003 | 80 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2003 | 73 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 183 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2007 | 798 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2003 | 79 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 165 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 576 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2003 | 191 | 0.010 |
Why?
|
| Austria | 2 | 1992 | 21 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2003 | 312 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2003 | 226 | 0.010 |
Why?
|
| Thrombospondins | 1 | 2001 | 14 | 0.010 |
Why?
|
| Versicans | 1 | 2001 | 15 | 0.010 |
Why?
|
| India | 2 | 1992 | 234 | 0.010 |
Why?
|
| South Carolina | 1 | 2000 | 10 | 0.010 |
Why?
|
| Consensus | 1 | 2003 | 512 | 0.010 |
Why?
|
| Guanine | 1 | 2001 | 58 | 0.010 |
Why?
|
| beta-Thromboglobulin | 1 | 2000 | 2 | 0.010 |
Why?
|
| DNA Ligases | 1 | 2000 | 15 | 0.010 |
Why?
|
| Missouri | 1 | 2000 | 42 | 0.010 |
Why?
|
| New York | 1 | 2000 | 69 | 0.010 |
Why?
|
| Taiwan | 1 | 2000 | 38 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2001 | 151 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 1153 | 0.010 |
Why?
|
| Adenine | 1 | 2001 | 110 | 0.010 |
Why?
|
| Arginine | 1 | 2003 | 340 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 1186 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 1571 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3748 | 0.010 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 1999 | 8 | 0.010 |
Why?
|
| Uncoupling Protein 1 | 1 | 1999 | 33 | 0.010 |
Why?
|
| Receptors, Glucagon | 1 | 1999 | 33 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1999 | 242 | 0.010 |
Why?
|
| Glucagon | 1 | 1999 | 146 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2011 | 3147 | 0.010 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 1999 | 77 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 422 | 0.010 |
Why?
|
| Information Systems | 1 | 1996 | 28 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 1995 | 17 | 0.010 |
Why?
|
| Time | 1 | 1995 | 92 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 573 | 0.010 |
Why?
|
| Wales | 1 | 1992 | 7 | 0.010 |
Why?
|
| Israel | 1 | 1992 | 44 | 0.010 |
Why?
|
| Germany | 1 | 1992 | 61 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 1991 | 22 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1991 | 39 | 0.010 |
Why?
|
| Sudan | 1 | 1991 | 2 | 0.010 |
Why?
|
| Hungary | 1 | 1991 | 7 | 0.010 |
Why?
|
| Malaysia | 1 | 1991 | 17 | 0.010 |
Why?
|
| Cholesterol Esters | 1 | 1991 | 12 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1991 | 780 | 0.000 |
Why?
|
| Thrombin | 1 | 1989 | 57 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1989 | 318 | 0.000 |
Why?
|
| Isoelectric Point | 1 | 1988 | 16 | 0.000 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1988 | 16 | 0.000 |
Why?
|
| Nucleotide Mapping | 1 | 1987 | 12 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1987 | 73 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1989 | 981 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1987 | 401 | 0.000 |
Why?
|